# Chapter 118: Other (or Unknown) Substance Use Disorder

# The Biological and Neurological Basis of Other (or Unknown) Substance Use Disorder

## Introduction

Other (or Unknown) Substance Use Disorder represents a significant and diagnostically challenging category within the spectrum of addictive disorders. As defined in frameworks such as the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), this classification encompasses problematic patterns of use involving substances not covered in other specific categories, such as prescription medications used non-medically, inhalants, and a vast, ever-evolving array of novel psychoactive substances (NPS), often referred to as "designer drugs" (Daley & Douaihy, 2019; Beebe & Walley, 1991). The category is inherently heterogeneous, including substances with diverse pharmacological profiles, from stimulants and depressants to hallucinogens and dissociatives (Daley & Douaihy, 2019; Hohmann et al., 2014). For instance, the abuse of antiparkinsonian drugs such as trihexyphenidyl is recognized under this diagnostic label (Garg & Rawat, 2023).

Substance use disorders (SUDs) are conceptualized as chronic, relapsing brain disorders characterized by a compulsion to seek and take a drug, a loss of control in limiting intake, and the emergence of a negative emotional state during abstinence (Franklin, 1995; Koob, 2020; Ungar et al., 2016). While the specific molecular targets of "other" substances vary widely, their capacity to induce dependence is rooted in their ability to engage and dysregulate the same fundamental neurobiological systems that underpin all addictive behaviors (Parolaro et al., 2005; Koob, 2013; Scuvée‐Moreau, 2013). These systems, primarily the brain's reward, stress, and executive function circuits, undergo profound neuroadaptive changes with repeated substance exposure, leading to the core features of addiction: tolerance, withdrawal, craving, and continued use despite adverse consequences (Franklin, 1995; Koob, 2020; Lyvers, 1998).

The neurobiological basis of addiction is understood as a cyclical process involving three stages: binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation (Koob, 2013; Koob, 2020; Tyler & Leggio, 2024). Different substances may preferentially impact different stages; for example, stimulants like synthetic cathinones ("bath salts") produce intense euphoria characteristic of the binge/intoxication stage (Kyle et al., 2011; Varı̀ et al., 2018), while cessation of long-term sedative use can precipitate a severe withdrawal/negative affect state (Ciraulo & Ciraulo, 2008; Petursson, 1994). Understanding the biological mechanisms within this framework is critical for diagnosing, managing, and developing effective treatments for this diverse and challenging group of disorders. This chapter will synthesize the current evidence, drawn exclusively from the provided literature, on the neurobiological underpinnings of Other (or Unknown) Substance Use Disorder, exploring the common pathways and substance-specific effects that drive this complex condition.

## Neurobiological Systems

The development and maintenance of Other (or Unknown) SUD, like all addictive disorders, is fundamentally rooted in drug-induced alterations to the brain's complex neurocircuitry. While the substances within this category are pharmacologically diverse, they converge upon key neurobiological systems that regulate motivation, reward, stress, and executive control. Chronic exposure to these agents leads to maladaptive neuroplasticity, driving the transition from voluntary use to compulsive, uncontrolled substance seeking and consumption (Antonio & Alfredo, 2012; Parolaro et al., 2005; Koob et al., 2008).

### Neurotransmitter Systems and Neuropharmacology

The psychoactive effects, reinforcing properties, and neuroadaptive changes associated with Other (or Unknown) SUDs are mediated through interactions with multiple neurotransmitter systems. The primary systems implicated include the dopaminergic, serotonergic, GABAergic, glutamatergic, and, to a lesser extent, noradrenergic, cholinergic, and endogenous opioid and cannabinoid systems.

**The Dopaminergic System:** The mesolimbic dopamine pathway, originating in the ventral tegmental area (VTA) and projecting to the nucleus accumbens (NAc), is a central substrate for the rewarding and reinforcing effects of most, if not all, drugs of abuse (Antonio & Alfredo, 2012; Koob, 2013; Scuvée‐Moreau, 2013). This system is a primary target for many substances classified under "Other SUDs," particularly stimulants. Synthetic cathinones, cocaine, and amphetamines produce their intense euphoria and reinforcing effects by increasing synaptic dopamine concentrations in the NAc (Varı̀ et al., 2018; Benowitz, 1993; Caldwell & Sever, 1974). They achieve this primarily by blocking the dopamine transporter (DAT), thus inhibiting dopamine reuptake, or by stimulating dopamine release (Antonio & Alfredo, 2012; Caldwell & Sever, 1974; Varı̀ et al., 2018). The euphorigenic effects of anticholinergic drugs like trihexyphenidyl are also explained, in part, by the inhibition of dopamine reuptake and storage (Garg & Rawat, 2023). Chronic overstimulation of this system leads to neuroadaptations, such as a downregulation of dopamine D2 receptors, which is hypothesized to contribute to the anhedonia and motivational deficits seen during withdrawal and the compulsive drive to seek the drug (Wise, 1982; Koob, 2020; Nigg et al., 2002).

**The Serotonergic System:** Serotonin (5-HT) systems are critically involved in regulating mood, anxiety, impulsivity, and sleep, and are major targets for hallucinogenic and entactogenic substances (Parolaro et al., 2005; Scuvée‐Moreau, 2013). 3,4-methylenedioxymethamphetamine (MDMA, or "ecstasy"), a common "club drug," is a potent releaser and reuptake inhibitor of serotonin, which accounts for its desired effects of empathy, euphoria, and enhanced sociability (de la Torre et al., 2004; Smith et al., 2002). Other hallucinogens, such as lysergic acid diethylamide (LSD) and psilocybin, exert their profound perceptual and cognitive effects primarily through agonist activity at serotonin 5-HT2A receptors (Pechnick et al., 2014; Latt et al., 2009). Chronic, heavy use of substances like MDMA is associated with long-term damage to serotonergic neurons, which may underlie the persistent depression, anxiety, and cognitive deficits reported in some users (Parrott, 2006; de la Torre et al., 2004).

**GABA and Glutamate Systems:** The balance between the brain's primary inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), and its primary excitatory neurotransmitter, glutamate, is essential for central nervous system (CNS) homeostasis. This balance is profoundly disrupted by many substances. Sedative-hypnotics, including benzodiazepines and gamma-hydroxybutyrate (GHB), exert their effects by enhancing GABAergic transmission, leading to CNS depression (Ciraulo & Ciraulo, 2008; Mattison & Cherner, 2005). Chronic use leads to a compensatory downregulation of GABA receptor function and an upregulation of glutamate systems (Tyler & Leggio, 2024). Upon cessation, this results in a state of CNS hyperexcitability, manifesting as the anxiety, insomnia, and seizures characteristic of withdrawal (Petursson, 1994; Thompson & Weber, 2021). Conversely, dissociative anesthetics like ketamine and phencyclidine (PCP) act as antagonists at the N-methyl-D-aspartate (NMDA) glutamate receptor, producing their characteristic hallucinatory and dissociative effects (Andrade, 2017; Perłowski et al., 2024; Jacob et al., 1981). Maladaptive plasticity in glutamatergic pathways, particularly those projecting from the prefrontal cortex, is thought to be a key mechanism in the development of compulsive drug-seeking and relapse (Koob, 2020; Antonio & Alfredo, 2012).

**Other Neurotransmitter Systems:**
*   **Norepinephrine:** This system is involved in arousal, vigilance, and the stress response. Stimulants such as cocaine, amphetamines, and synthetic cathinones also increase norepinephrine levels, contributing to their sympathomimetic effects like tachycardia and hypertension (Benowitz, 1993; Varı̀ et al., 2018; Antonio & Alfredo, 2012).
*   **Acetylcholine:** The abuse potential of certain prescription drugs, such as the antiparkinsonian agent trihexyphenidyl, is linked to their anticholinergic properties, specifically the blockade of muscarinic receptors (Garg & Rawat, 2023). Chronic blockade can lead to acetylcholine receptor hypersensitivity, which may explain the emergence of severe motor and mood symptoms upon withdrawal (Garg & Rawat, 2023).
*   **Endocannabinoid and Opioid Systems:** These endogenous systems play a crucial role in modulating reward, pain, and stress. The endocannabinoid system, in particular, is now understood to be involved in the motivational effects of a wide range of substances, not just cannabis, by modulating dopamine release in the reward pathway (Parolaro et al., 2005; Koob, 2020). Similarly, endogenous opioid peptides contribute to the hedonic effects of various rewards, including drugs of abuse (Noble & Roques, 2003; Koob et al., 2008).

### Neural Circuits and Functional Connectivity

The behavioral manifestations of Other (or Unknown) SUD are driven by drug-induced dysfunction across interconnected neural circuits. The prevailing neurobiological model of addiction posits a three-stage, three-circuit framework that becomes increasingly dysregulated with chronic substance use (Koob, 2013; Koob, 2020).

1.  **Binge/Intoxication Stage and the Basal Ganglia:** This stage is characterized by the rewarding effects of substances and the development of compulsive use patterns or habits. The key neural circuit involves the basal ganglia, particularly the VTA-NAc dopamine pathway, which is integral to reward and incentive salience (Koob, 2013; Tyler & Leggio, 2024). Stimulant "other" substances, such as synthetic cathinones and misused prescription stimulants, directly and powerfully activate this circuit, leading to intense euphoria and reinforcement of drug-taking behavior (Varı̀ et al., 2018; Espay et al., 2015). With repeated use, control of behavior shifts from the NAc (involved in goal-directed action) to the dorsal striatum, which mediates habit formation. This shift underlies the transition from voluntary to compulsive drug use, where substance-seeking becomes an automatic, stimulus-driven behavior (Campos, 2017; Koob et al., 2008).

2.  **Withdrawal/Negative Affect Stage and the Extended Amygdala:** Following the cessation of drug use, a negative emotional state emerges, characterized by dysphoria, anxiety, and irritability (Koob, 2020). This stage is driven by dysfunction within the extended amygdala, a circuit that includes the central nucleus of the amygdala, the bed nucleus of the stria terminalis, and a portion of the NAc shell (Koob, 2020). This system mediates the brain's stress and fear responses. Chronic substance use results in two primary neuroadaptations: a hypofunctioning of the reward system (a reward deficit) and a hyperfunctioning of the brain's stress systems (a stress surfeit), including hyperactivity of corticotropin-releasing factor (CRF) and norepinephrine systems (Koob, 2020; Heilig, 2023; Tyler & Leggio, 2024). This creates a powerful state of negative reinforcement, or "hyperkatifeia," where the individual is motivated to resume drug use not for pleasure, but to alleviate the aversive emotional and physical symptoms of withdrawal (Koob, 2020; Koob, 2013). This mechanism is prominent in withdrawal from sedatives like benzodiazepines and GHB, where severe anxiety and agitation are common (Petursson, 1994; Thompson & Weber, 2021).

3.  **Preoccupation/Anticipation Stage and the Prefrontal Cortex:** This stage involves craving and executive function deficits, such as impaired decision-making and loss of impulse control, which are hallmarks of addiction (Koob, 2013; Koob, 2020). The primary neural substrate is the prefrontal cortex (PFC), which normally exerts top-down inhibitory control over the reward- and stress-driven circuits in the basal ganglia and extended amygdala (Koob et al., 2008). Chronic use of many substances, including inhalants and stimulants, is associated with hypofrontality, or reduced PFC function (Ron, 1986; Majewska, 1996). This impairment compromises an individual's ability to resist strong urges and make decisions that favor long-term health over immediate gratification, thus promoting relapse (Koob, 2020; López‐Caneda et al., 2013). The insular cortex is also critically involved in this stage, particularly in mediating conscious craving (Tyler & Leggio, 2024).

In summary, the diverse substances within the "Other (or Unknown)" category, despite their varied initial targets, ultimately induce a common pathology: a dysregulation of the brain's core motivational, emotional, and executive circuits. This leads to a state where reward systems are blunted, stress systems are hyperactive, and the cognitive capacity to regulate behavior is compromised, creating a powerful and persistent drive for continued substance use.

## Genetic and Molecular Basis

The development of an Other (or Unknown) Substance Use Disorder is not an inevitable consequence of substance exposure. It arises from a complex interplay between environmental factors and an individual's biological vulnerability, a significant portion of which is genetically determined (Winters & Ingwalson, 2022; Kolla & Hocker, 2021). While specific genes for this heterogeneous category are not well-defined, general principles of addiction genetics and molecular neurobiology provide a foundational understanding of the underlying susceptibility and the persistent brain changes that characterize the disorder.

### Genetic Factors and Heritability

Substance use disorders, as a class, are known to be heritable (Koob et al., 2008; Ivlieva, 2011). Family, twin, and adoption studies on more common SUDs, such as alcohol use disorder, indicate that genetic factors account for a substantial portion of the variance in risk, with heritability estimates around 60% (DiMartini, 2007). This genetic predisposition is not deterministic but rather confers a vulnerability that increases the likelihood of developing an SUD when exposed to the substance and relevant environmental stressors (Winters & Ingwalson, 2022; Smith et al., 2002).

This vulnerability is likely polygenic, involving numerous genes that influence various aspects of neurobiology and behavior (DiMartini, 2007). Candidate genes are those involved in neurotransmitter synthesis, transport, and receptor function, particularly within the dopamine, serotonin, and GABA systems (Ivlieva, 2011). For example, genetic variations in dopamine receptors or transporters could influence an individual's sensitivity to the rewarding effects of stimulants (Nigg et al., 2002). Similarly, polymorphisms in enzymes that metabolize drugs, such as the cytochrome P450 system, can affect drug concentrations and duration of action, thereby influencing both therapeutic effects and the potential for toxicity and dependence (Shah, 2005; Wolf & Griffiths, 1991). Personality traits with a genetic basis, such as impulsivity and novelty seeking, are also significant risk factors for initiating and maintaining substance use (Voon et al., 2007; Huang & Tsai, 2012). These traits are associated with underlying differences in brain circuitry that may predispose individuals to the reinforcing effects of various substances (Bari et al., 2010).

### Molecular and Cellular Mechanisms

The transition from voluntary drug use to the compulsive state of addiction is fundamentally a process of drug-induced neural plasticity (Antonio & Alfredo, 2012; Parolaro et al., 2005). Repeated exposure to psychoactive substances triggers a cascade of molecular and cellular adaptations in the brain that are long-lasting and underlie the persistent nature of addiction (Kalivas et al., 2003; Lyvers, 1998).

**Synaptic Plasticity and Gene Expression:** At the molecular level, addictive drugs alter synaptic strength and structure through mechanisms similar to those involved in learning and memory (Müller, 2013; Velásquez-Martínez & Ortíz, 2014). Acute drug exposure initiates changes in intracellular signaling pathways. For example, many drugs of abuse lead to an up-regulation of the cyclic AMP (cAMP) second messenger pathway, which in turn activates transcription factors like the cAMP response element-binding protein (CREB) (Antonio & Alfredo, 2012). CREB activation is thought to mediate aspects of tolerance and physical dependence, contributing to the negative emotional state during withdrawal (Antonio & Alfredo, 2012).

In contrast, another transcription factor, ΔFosB (a truncated and highly stable form of FosB), accumulates in the NAc and dorsal striatum with chronic drug exposure (Antonio & Alfredo, 2012). Unlike the transient activation of CREB, ΔFosB persists for weeks or months after drug cessation. This persistence is thought to be a key molecular switch that mediates long-term sensitization to drug effects and contributes to the heightened vulnerability to relapse (Antonio & Alfredo, 2012; Kalivas et al., 2003). These transcription factors alter the expression of numerous downstream genes, leading to lasting changes in neuronal structure and function, such as alterations in dendritic spine density and receptor expression (Koob et al., 2008).

**Opponent Process and Allostasis:** A crucial concept for understanding the molecular basis of addiction is the opponent-process theory, which posits that the brain attempts to maintain homeostasis by counteracting the acute effects of a drug (Koob, 2020; Tyler & Leggio, 2024). Acutely, a substance may produce a positive, hedonic state (A-process). The brain responds by initiating a counter-regulatory, negative state (B-process). With repeated drug use, the A-process may weaken (tolerance), while the B-process strengthens and becomes sensitized (Isbell & Fraser, 1950; Koob, 2020). When the drug is withdrawn, this powerful, unopposed B-process manifests as the dysphoria, anxiety, and irritability of the withdrawal syndrome (Koob, 2020).

This chronic dysregulation leads to a state of allostasis, where the baseline hedonic set-point is lowered (Koob, 2020; Heilig, 2023). The individual is no longer seeking the drug to achieve euphoria but to temporarily escape this persistent negative emotional state—a hallmark of negative reinforcement that powerfully drives compulsive drug use (Koob, 2020; Koob, 2013). This allostatic load involves between-system neuroadaptations, including sensitization of brain stress systems (e.g., CRF, norepinephrine, dynorphin) and dysregulation of anti-stress systems (e.g., neuropeptide Y, endocannabinoids) (Koob, 2020; Heilig, 2023). These molecular changes within the extended amygdala are central to the negative affect stage of addiction and the concept of "hyperkatifeia," an intensified negative emotional state that drives relapse (Koob, 2020).

In conclusion, an individual's genetic makeup creates a spectrum of vulnerability to Other (or Unknown) SUDs. For those who engage in repeated use, these substances trigger profound and lasting changes in gene expression and cellular function. These adaptations reshape neural circuits, leading to a transition from reward-driven to habit-driven behavior and the emergence of a powerful, negatively reinforced state that perpetuates the cycle of addiction.

## Brain Structure and Function

The persistent behavioral patterns of Other (or Unknown) Substance Use Disorder are reflections of enduring changes in brain structure and function. While the source literature provides limited specific neuroimaging data, such as from functional magnetic resonance imaging (fMRI) or positron emission tomography (PET), it offers a consistent picture derived from clinical neurology, toxicology, and animal models. These sources indicate that chronic use of various "other" substances can lead to both gross structural damage and subtle, but critical, dysfunctions in the neural circuits governing cognition, emotion, and behavior.

### Neuroimaging and Neuroanatomical Findings

Neuroimaging techniques are essential for investigating the neurological consequences of substance abuse, although their application to the diverse class of "other" substances is less systematic than for more common drugs. The available evidence points to several key areas of structural and functional impact.

**Structural Brain Changes:** Chronic abuse of certain substances within this category is unequivocally associated with neurotoxicity and structural brain damage. Inhalant abuse, particularly of volatile substances containing toluene or n-hexane, can cause significant and often irreversible neurological damage (Howard et al., 2015; Ron, 1986). Neuroimaging studies in chronic solvent abusers have revealed diffuse cerebral atrophy, ventricular enlargement, and white matter abnormalities (Ron, 1986; Farre Albaladejo, 1989; Barroso Moguel et al., 1993). These structural changes are the substrate for the profound and persistent cognitive deficits, cerebellar ataxia, and dementia observed in this population (Ron, 1986; Axelson, 1996). Similarly, chronic cocaine abuse has been linked to cerebral atrophy (Barroso Moguel et al., 1993).

**Cerebrovascular Complications:** A major category of neurological harm from stimulant substances like cocaine and amphetamines involves the cerebrovascular system. These drugs are potent vasoconstrictors and can cause severe, acute hypertension (Benowitz, 1993; Díez‐Tejedor et al., 1989). Consequently, their use is a significant risk factor for both ischemic and hemorrhagic stroke, particularly in young adults (Rowbotham & Lowenstein, 1990; Kramer et al., 1990; Díez‐Tejedor et al., 1989). Angiographic studies have revealed lesions suggestive of vasculopathy in users (Díez‐Tejedor et al., 1989). Other vascular complications include subarachnoid hemorrhage and aneurysms (Karila et al., 2009; Kramer et al., 1990). These events result in focal areas of brain damage, leading to a wide range of neurological deficits depending on the location and extent of the injury (Rowbotham & Lowenstein, 1990).

**Seizures and Excitotoxicity:** Seizures are a common neurological complication of both intoxication and withdrawal from numerous psychoactive substances (Brust, 2002; Kramer et al., 1990). Stimulants such as cocaine and amphetamines can provoke seizures through excessive CNS stimulation and lowering of the seizure threshold (Kramer et al., 1990; Zagnoni & Albano, 2002). Withdrawal from CNS depressants like benzodiazepines and alcohol also notoriously leads to seizures due to a state of neuronal hyperexcitability (Petursson, 1994; Fialip et al., 1987). This hyperexcitability is related to the aforementioned neuroadaptive changes in GABA and glutamate systems (Antonio & Alfredo, 2012). In severe cases, this can progress to status epilepticus, a life-threatening medical emergency (Sabo-Graham & Seay, 1998; Tsai & Liou, 2015). Some designer drugs, such as synthetic cathinones, have also been associated with seizures (Kyle et al., 2011).

### Functional Brain Changes and Cognitive Impairment

Beyond overt structural damage, the chronic use of "other" substances induces functional changes in brain circuits, leading to a broad spectrum of cognitive and behavioral impairments. These deficits often persist long after the cessation of drug use and contribute significantly to the disability associated with addiction (Carlin & O'Malley, 1996; Parsons, 1987).

**Executive Dysfunction:** The prefrontal cortex (PFC) is particularly vulnerable to the effects of chronic drug use (Majewska, 1996). The PFC is responsible for executive functions, which include planning, organization, decision-making, mental flexibility, and impulse control (Brody, 2014). Chronic use of substances like cocaine, stimulants, and cannabis is associated with deficits in these functions (Lorea Conde et al., 2010; Karila et al., 2009; Karila et al., 2014). This executive dysfunction is a core component of the preoccupation/anticipation stage of addiction, reflecting a weakened top-down control over behavior and contributing to poor judgment, risk-taking, and an inability to inhibit the compulsive drive to use drugs (Koob, 2020; Bari et al., 2010).

**Memory and Attention:** Memory and attention are frequently impaired by chronic substance use. Cannabis use is associated with deficits in attention, learning, and memory, which may persist even after abstinence (Karila et al., 2014; Queiroz et al., 2025; Ashton, 2018). Similarly, recreational ecstasy (MDMA) users have shown deficits in working and episodic memory that can persist for at least two years after cessation of use (Ward et al., 2006; Parrott, 2006). The mechanisms for these deficits are thought to involve drug-induced damage or dysfunction in the hippocampus and PFC (Karila et al., 2014; Dervaux, 2013). Attention Deficit Hyperactivity Disorder (ADHD) is a common comorbidity with SUDs, and it is hypothesized that individuals with pre-existing attentional deficits may be more vulnerable to substance abuse, potentially as a form of self-medication (Wilens, 1998; Khantzian, 1990; Sullivan & RUDNIK‐LEVIN, 2001).

**Psychosis and Perceptual Disturbances:** Many substances in this category can induce acute, transient psychotic states characterized by paranoia, delusions, and hallucinations (Beebe & Walley, 1991; Morton, 1999). Stimulants like cocaine, amphetamines, and synthetic cathinones are well-known for producing paranoid psychosis that can be indistinguishable from schizophrenia (Bell, 1973; Morton, 1999; Kyle et al., 2011). Hallucinogens such as LSD and psilocybin, and dissociatives like PCP and ketamine, produce profound alterations in perception, thought, and mood by definition (Pechnick et al., 2014; Williams & Erickson, 2000). While these effects are typically transient, some individuals may experience prolonged psychotic reactions or "flashbacks"—the re-experiencing of perceptual distortions long after the drug has been eliminated (Strassman, 1984; Pierce, 1973). In vulnerable individuals, substance use, particularly cannabis, may precipitate or exacerbate a primary psychotic disorder like schizophrenia (Radhakrishnan et al., 2014; D’Souza, 2023).

In conclusion, the use of "other" substances can have devastating effects on brain structure and function. These range from acute, life-threatening events like stroke and seizures to chronic, debilitating conditions such as dementia and persistent cognitive impairment. These neurological consequences are not merely side effects but are integral to the pathology of addiction, contributing to impaired judgment and loss of control that perpetuate the disorder.

## Developmental Neurobiology

The trajectory of Other (or Unknown) Substance Use Disorder is profoundly influenced by developmental factors. The brain does not mature uniformly; different regions and circuits develop at different rates, creating specific windows of vulnerability. Adolescence, in particular, is a critical period of neurodevelopmental change that coincides with the peak age of onset for substance use initiation (McGorry et al., 2011; de Girolamo et al., 2011). Furthermore, exposure to substances during the prenatal period can alter the developmental trajectory of the brain, establishing a biological predisposition for later psychopathology, including SUDs (Winters & Ingwalson, 2022).

### Adolescence as a Critical Period of Vulnerability

Adolescence is characterized by significant remodeling of neural circuits, particularly those involving the prefrontal cortex (PFC), limbic system, and their connections (McGorry & Yung, 2020; Hyytiä, 2015). The PFC, which is responsible for executive functions like impulse control, decision-making, and risk assessment, is one of the last brain regions to fully mature, with development continuing into the early twenties (López‐Caneda et al., 2013). In contrast, the brain's reward and emotion-processing circuits, such as the NAc and amygdala, mature earlier (López‐Caneda et al., 2013).

This developmental mismatch creates a neurobiological imbalance: adolescents possess a mature, highly sensitive reward system that drives pleasure-seeking and novelty-seeking behaviors, but an immature PFC that provides weak top-down inhibitory control (Winters & Ingwalson, 2022; López‐Caneda et al., 2013). This combination makes adolescents biologically prone to impulsivity, risk-taking, and heightened sensitivity to the rewarding effects of drugs (Schwartz, 1984; Bari et al., 2010). Consequently, initial experiences with substances like alcohol, cannabis, or novel stimulants are more likely to occur during this period (Takahashi & Franklin, 1996; McArdle & Angom, 2012).

Exposure to psychoactive substances during this critical developmental window can disrupt normal brain maturation. For example, substantial binge drinking or chronic cannabis use during adolescence has been associated with alterations in brain structure, including reduced gray matter volume and compromised white matter integrity, particularly in the frontal and temporal lobes (Hyytiä, 2015; Alfonso‐Loeches & Guerri, 2011). These structural alterations may underlie the cognitive impairments observed in adolescent substance users and may represent a long-term neurological consequence of early use (Hyytiä, 2015; Karila et al., 2014). Because the adolescent brain exhibits heightened neuroplasticity, it may be more susceptible to the long-lasting, addiction-related changes in synaptic strength and gene expression driven by drug exposure (Antonio & Alfredo, 2012; Kalivas et al., 2003). Therefore, early onset of substance use is one of the strongest predictors of developing a severe and chronic SUD in adulthood (Copeland et al., 2014; Wilens, 1998).

### Prenatal Substance Exposure

The developing fetal brain is exceptionally vulnerable to the toxic effects of psychoactive substances consumed by the mother during pregnancy (Forray, 2016; Ornoy, 2002). Substances such as alcohol, nicotine, cocaine, and opioids readily cross the placental barrier and can interfere with fundamental neurodevelopmental processes, including neuronal proliferation, migration, and synaptogenesis (Ornoy, 2002; Alfonso‐Loeches & Guerri, 2011).

Prenatal exposure to these substances can lead to a spectrum of adverse outcomes. For example, heavy maternal alcohol use can result in fetal alcohol spectrum disorders, which are characterized by a range of physical, cognitive, and behavioral impairments, including intellectual disability and symptoms of ADHD (Ornoy, 2002; Lockhart, 2001; Evrard, 2010). Prenatal cocaine exposure has been associated with more subtle but significant long-term deficits in attention, arousal regulation, and executive function that persist into adolescence (Dubovsky, 2015; Ornoy, 2002). Similarly, prenatal exposure to opioids is linked to a neonatal abstinence syndrome characterized by CNS hyperarousal, and may be associated with later behavioral problems, including impulsivity and attentional deficits (Hutchings, 1982; Dydyk et al., 2021).

These early insults to the developing brain can establish a lasting biological vulnerability for future psychiatric problems (Winters & Ingwalson, 2022; Schepis et al., 2011). By altering the structural and functional organization of key neural circuits, particularly the dopamine-mediated reward system and the prefrontal circuits for executive control, prenatal substance exposure may increase an individual's sensitivity to the reinforcing effects of drugs and impair their ability to regulate substance use later in life (Schepis et al., 2011; Johnson, 2016). Thus, prenatal exposure is considered a significant, albeit non-specific, risk factor for the later development of SUDs (Winters & Ingwalson, 2022).

### Early Life Stress and Trauma

Adverse childhood experiences, such as physical, sexual, or emotional abuse and neglect, are potent risk factors for the development of a wide range of mental health problems, including SUDs (Verma & Agrawal, 2021; Arnow, 2004). Early life stress can have profound and enduring effects on neurodevelopment, particularly on the brain's stress-response systems (Wand, 2008; Johnson & Buisman‐Pijlman, 2016). Chronic stress dysregulates the hypothalamic-pituitary-adrenal (HPA) axis and central CRF systems, leading to a state of heightened stress reactivity that can persist into adulthood (Stratakis et al., 1995; Wand, 2008).

This stress-induced neurobiological profile overlaps significantly with the neuroadaptations seen in addiction. A sensitized stress system can increase an individual's vulnerability to the rewarding effects of drugs, which may be used as a form of "self-medication" to cope with the negative affective states associated with trauma (Khantzian, 1990; Wand, 2008; Sinha, 2018). Furthermore, early life trauma can impair the development of the PFC, compromising executive functions and impulse control, which further elevates the risk for engaging in hazardous substance use (Kavanaugh et al., 2016; Sinha, 2018). The interaction between early life adversity and genetic predisposition likely creates a powerful synergistic risk for the development of severe and complex SUDs (Johnson & Buisman‐Pijlman, 2016; Schepis et al., 2011).

## Treatment Mechanisms

The treatment of Other (or Unknown) Substance Use Disorder, like all SUDs, requires a comprehensive, biopsychosocial approach that addresses the complex neurobiological changes underlying the condition as well as the associated psychological and social factors (Rao & Kumar, 2008; Daley & Douaihy, 2019). Interventions are broadly divided into pharmacological and psychosocial approaches, which are often most effective when used in combination (Daley & Douaihy, 2019). These treatments aim to manage withdrawal, reduce craving, prevent relapse, and improve overall functioning by targeting the dysregulated neural circuits.

### Pharmacological Interventions

Pharmacotherapy for SUDs operates on several key neurobiological principles: managing acute intoxication and withdrawal, reducing the reinforcing effects of the substance, and alleviating craving or protracted withdrawal symptoms (Rao & Kumar, 2008; Law & Nutt, 2012). While there are no medications specifically approved for the broad category of "Other SUDs," principles derived from the treatment of more common SUDs can be applied, and some agents are used off-label for specific substances within this class.

**Management of Intoxication and Withdrawal:** For acute intoxication with CNS stimulants like synthetic cathinones or cocaine, which can present with severe agitation, psychosis, and sympathomimetic toxicity, the primary pharmacological intervention is symptomatic and supportive (Keary et al., 2013; Smith et al., 2002). Benzodiazepines are often used to manage agitation and reduce cardiovascular stress by enhancing GABAergic inhibition (Keary et al., 2013; Monotti, 1993; Garza-Treviño, 1988). In cases of severe psychosis, antipsychotic medications that block dopamine D2 receptors may be necessary (Garza-Treviño, 1988; Fontalba-Navas & Caparros-del-Moral, 2015).

Conversely, withdrawal from CNS depressants such as benzodiazepines requires careful management to prevent life-threatening complications like seizures and delirium (Petursson, 1994; Yersin, 1999). The standard approach involves substituting the abused short-acting agent with a long-acting benzodiazepine (e.g., diazepam) or a barbiturate (e.g., phenobarbital) and then gradually tapering the dose over weeks to months (Thompson & Weber, 2021; Landry et al., 1992). This strategy allows the GABAergic system to gradually re-adapt to the absence of the drug, mitigating the risk of severe CNS hyperexcitability (Landry et al., 1992; Wolf & Griffiths, 1991).

**Relapse Prevention and Craving Reduction:** The development of medications for relapse prevention is a major focus of addiction medicine. These agents typically work by one of two mechanisms: blocking the rewarding effects of the drug (antagonist therapy) or substituting it with a safer, longer-acting agonist (agonist maintenance therapy) (Daley & Douaihy, 2019). For example, naltrexone, an opioid antagonist, is used in alcohol and opioid dependence to block the reinforcing effects mediated by the endogenous opioid system (Rao & Kumar, 2008; Dongier, 2003). While there are no approved antagonists for most "other" substances, this principle guides research.

Agonist maintenance, exemplified by methadone for opioid use disorder, aims to stabilize the dysregulated neurobiological systems by providing a steady level of receptor stimulation, thereby reducing withdrawal, craving, and illicit drug use (Ruiz et al., 2007). Although not standard for most "other" substances, this principle is being explored. For instance, prescription stimulants are being investigated for stimulant use disorders (Buoli et al., 2015; Shulman et al., 2023).

Other medications target the craving and negative affect associated with protracted withdrawal. Bupropion, which has effects on dopamine and norepinephrine, is used for nicotine dependence and may have some utility in stimulant use disorders (Rao & Kumar, 2008; Shulman et al., 2023). Anticonvulsants like gabapentin are used off-label to manage withdrawal symptoms from alcohol and other substances, possibly by stabilizing neuronal excitability (Howland, 2014; Tiglao et al., 2021).

### Psychosocial Interventions and their Biological Basis

Psychosocial treatments are considered the foundation of any comprehensive SUD treatment program and are essential for long-term recovery (Rao & Kumar, 2008; Daley & Douaihy, 2019). While these interventions are behavioral, their efficacy is rooted in their ability to promote neuroplasticity and restore function in brain circuits compromised by addiction, particularly the PFC.

**Cognitive Behavioral Therapy (CBT):** CBT is one of the most empirically supported therapies for SUDs (Rao & Kumar, 2008; Neavins et al., 2008). It helps individuals identify and modify maladaptive thought patterns and behaviors associated with substance use. From a neurobiological perspective, CBT works by strengthening top-down cognitive control from the PFC over subcortical regions that drive impulsive and compulsive behaviors (Koob, 2020). By teaching coping skills, stress management, and strategies to avoid high-risk situations, CBT helps patients re-regulate the brain's stress and reward systems and improve executive function (Rao & Kumar, 2008; Neavins et al., 2008).

**Motivational Enhancement Therapy (MET) and Motivational Interviewing (MI):** Many individuals with SUDs are ambivalent about changing their behavior. MET/MI is a client-centered approach designed to resolve this ambivalence and enhance intrinsic motivation to change (Rao & Kumar, 2008; Neavins et al., 2008). Neurobiologically, this process can be conceptualized as engaging the PFC's decision-making and goal-setting functions to override the automatic, habit-driven behaviors mediated by the dorsal striatum (Koob et al., 2008).

**Contingency Management (CM):** CM utilizes principles of operant conditioning by providing tangible rewards (e.g., vouchers) for objective evidence of abstinence, such as negative urine toxicology screens (Neavins et al., 2008; Shulman et al., 2023). This approach directly competes with the reinforcing properties of the drug by providing an alternative, immediate reward for non-use. It leverages the brain's reward circuitry, helping to shift incentive salience away from the drug and toward pro-recovery behaviors (Rao & Kumar, 2008).

**Community Reinforcement and Family Approaches:** These interventions focus on rearranging the individual's environment to make a sober lifestyle more rewarding than a substance-using one (Rao & Kumar, 2008). By improving family relationships, vocational skills, and social networks, these therapies increase the availability of natural rewards, which can help restore function in the brain's reward pathways that have been blunted by chronic drug use (Rao & Kumar, 2008; Handlarz et al., 1976).

In summary, effective treatment for Other (or Unknown) SUD requires a multi-pronged approach. Pharmacological agents can provide crucial stability during the acute phases of withdrawal and help reduce the neurobiological drive to use. Simultaneously, psychosocial interventions are vital for teaching the cognitive and behavioral skills needed to manage cravings, cope with stress, and rebuild a life in which abstinence is more rewarding than substance use, thereby fostering long-term neuroplastic changes that support recovery.

## Future Directions

The study of the biological and neurological basis of Other (or Unknown) Substance Use Disorder is a field characterized by both significant challenges and emerging opportunities. The dynamic and clandestine nature of the substances involved, particularly NPS, means that clinical and scientific knowledge often lags behind street-level trends (Hohmann et al., 2014; Coman et al., 2019). Future research must be agile and multidisciplinary to address the complex neurobiological questions posed by this heterogeneous disorder.

A primary challenge is the sheer diversity and rapid evolution of the substances in this category. The market for "designer drugs" constantly introduces new chemical entities, from synthetic cannabinoids and cathinones to novel phenethylamines and dissociatives (Beebe & Walley, 1991; Hohmann et al., 2014; Varı̀ et al., 2018). Each new compound possesses a unique pharmacological profile, and their long-term neurological and psychiatric consequences are almost entirely unknown (Hohmann et al., 2014; Wojtyła-Buciora et al., 2023). A critical future direction is the development of rapid and systematic preclinical screening platforms to characterize the neuropharmacology, toxicity, and abuse potential of these emerging substances. This would provide crucial, timely information to clinicians in emergency departments and addiction treatment settings who are often faced with managing intoxications from completely unknown compounds (Shah & Baum, 2018; Harry, 1997).

Furthermore, the prevalence of polysubstance use complicates the attribution of specific neurobiological effects to any single agent (Kosten, 1991; Miller & Gold, 1990). Users of "other" substances frequently consume them in combination with alcohol, cannabis, or other drugs, leading to complex pharmacokinetic and pharmacodynamic interactions that can unpredictably alter toxicity and clinical presentation (Kosten, 1991; van Amsterdam et al., 2023). Future research should employ sophisticated preclinical models of polysubstance use and advanced toxicological analyses in clinical populations to disentangle the effects of these combinations on the brain (Kintz et al., 2025).

From a neurobiological standpoint, there is a pressing need for longitudinal studies that track the neurological and cognitive consequences of using these substances over time. While cross-sectional studies have identified associations between chronic use of solvents or MDMA and brain abnormalities (Ron, 1986; Ward et al., 2006), prospective neuroimaging and neuropsychological studies are needed to establish causality and determine the potential for recovery with abstinence. Such studies could clarify whether the observed deficits are a direct consequence of neurotoxicity or are related to pre-existing vulnerabilities (Carlin & O'Malley, 1996).

The development of effective pharmacotherapies remains a significant hurdle, particularly for stimulant use disorders, which encompass many NPS (Graddy & Rastegar, 2020; Sevarino & Shelby, 2015). The search for medications that can effectively reduce craving and prevent relapse for substances like synthetic cathinones is a high priority. Future research should continue to explore novel pharmacological targets beyond the monoamine systems, potentially including glutamatergic modulators, agents targeting the brain's stress systems (e.g., CRF antagonists), or neuroimmune pathways (Heilig, 2023; Koob, 2020). The repurposing of existing medications also holds promise; for example, the potential utility of antidepressants or mood stabilizers in dual-diagnosis patients requires further investigation (Buoli et al., 2015; Maremmani et al., 2010).

Another vital area for future inquiry is the identification of biomarkers that can predict vulnerability, disease progression, and treatment response. Genetic markers, neuroimaging signatures, or peripheral markers of neuroinflammation could help stratify individuals at high risk for developing an SUD upon exposure to a novel substance or predict who is most likely to benefit from a particular pharmacological or psychosocial intervention (Ivlieva, 2011; Koob et al., 2008). This would be a crucial step toward personalized medicine in the field of addiction.

Finally, the boundary between recreational use and the development of a disorder is a key area for investigation. Understanding the neurobiological factors that mediate the transition from controlled, occasional use to compulsive, harmful use is fundamental to addiction science (Koob, 2013; Vanderschuren, 2008). This research could inform targeted prevention strategies aimed at adolescents and young adults, the populations most frequently engaged in the use of NPS, to halt the progression to a chronic disorder before irreversible neurological harm occurs (McArdle & Angom, 2012; Hohmann et al., 2014).

In conclusion, the landscape of Other (or Unknown) Substance Use Disorder is complex and continually shifting. Addressing this public health challenge will require a concerted effort to integrate forensic toxicology, preclinical pharmacology, clinical neuroscience, and public health surveillance. By elucidating the fundamental mechanisms of action and the long-term neurobiological consequences of these diverse substances, the scientific community can pave the way for more effective prevention, diagnosis, and treatment strategies.

## Conclusion

Other (or Unknown) Substance Use Disorder represents a diverse and challenging frontier in addiction medicine. This diagnostic category captures a wide array of psychoactive compounds, from misused prescription medications like anticholinergics and sedatives to a constantly evolving landscape of novel psychoactive substances and inhalants (Daley & Douaihy, 2019; Garg & Rawat, 2023; Howard et al., 2015). Despite the pharmacological heterogeneity of these agents, the biological and neurological underpinnings of the addictive process converge on a common set of principles that govern all substance use disorders. The disorder is fundamentally a disease of the brain, characterized by a pathological cycle of binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation, which is driven by profound and persistent drug-induced neuroadaptations (Koob, 2020; Franklin, 1995).

The neurobiological core of this disorder lies in the dysregulation of key neural circuits. The mesolimbic dopamine system, central to reward and motivation, is powerfully hijacked by many of these substances, creating intense reinforcing effects that drive initial and continued use (Antonio & Alfredo, 2012; Scuvée‐Moreau, 2013). With chronic exposure, neuroplastic changes lead to a desensitization of these reward pathways and a simultaneous sensitization of the brain's stress systems, centered in the extended amygdala (Koob, 2020). This results in a shift from drug-seeking for pleasure (positive reinforcement) to drug-seeking for relief from a dysphoric, anxious, and irritable withdrawal state (negative reinforcement) (Koob, 2020; Heilig, 2023). Compounding this is a progressive erosion of executive function, mediated by the prefrontal cortex, which compromises judgment, decision-making, and impulse control, making it increasingly difficult for the individual to regulate their substance use despite catastrophic consequences (Koob et al., 2008; López‐Caneda et al., 2013).

While these overarching principles apply broadly, the specific neurotoxic profiles of individual substances contribute to the varied clinical presentations. Stimulants may lead to cerebrovascular accidents and psychosis (Rowbotham & Lowenstein, 1990; Bell, 1973), inhalants to diffuse cerebral atrophy and dementia (Ron, 1986), and entactogens like MDMA to long-term serotonergic deficits (Parrott, 2006). Vulnerability to these outcomes is not uniform; it is shaped by a complex interplay of genetic predispositions, developmental factors—with adolescence being a period of heightened risk—and environmental influences such as early life stress and trauma (Winters & Ingwalson, 2022; Wand, 2008).

The biological understanding of this disorder directly informs treatment strategies. Pharmacological interventions aim to correct the underlying neurochemical imbalances by managing withdrawal, blocking drug effects, or reducing craving, while psychosocial therapies such as CBT seek to restore top-down cognitive control and build coping mechanisms (Rao & Kumar, 2008; Daley & Douaihy, 2019). However, the evidence base for treating this specific SUD category is sparse, and management is often extrapolated from other SUDs. The rapid emergence of new substances presents a continuous challenge, demanding ongoing research to characterize their neurobiological effects and develop targeted interventions (Hohmann et al., 2014). Ultimately, a deeper comprehension of the shared and unique neurological mechanisms of these diverse substances is paramount to mitigating the significant personal and public health burden imposed by Other (or Unknown) Substance Use Disorder.


## References

1. Abascal, R. R., Sendin, P. M., & Juan, M. E. A. (2008). Adicciones en Anestesiología. Revista de la Escuela de Medicina Legal. https://doi.org/10.5209/rev_reml.2008.n9.50286
2. Abdallah, S. J., Poenaru, S., Corrales‐Medina, V., & Cowan, J. (2021). COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review. Therapeutic Advances in Infectious Disease. https://doi.org/10.1177/20499361211009385
3. Abdo, C. H. N. (2017). Sexualidade e doenças reumáticas. Revista Paulista de Reumatologia. https://doi.org/10.46833/reumatologiasp.2017.16.3.6-12
4. Abdulqawi, R., Satia, I., Holt, K., Dockry, R., Sen, S., & Smith, J. A. (2021). An open-label study of the tolerability and potential efficacy of memantine for treating refractory chronic cough. ERJ Open Research. https://doi.org/10.1183/23120541.00447-2021
5. AbdulRahman, I., Yaqoob, Ú., & Bhatti, T. A. (2018). Sleep Disorders Caused by Depression. Clinical Depression. https://doi.org/10.4172/2572-0791.1000131
6. Abe, Y., & Germai, A. (2012). Insomnia and Its Correlates: Current Concepts, Epidemiology, Pathophysiology and Future Remarks. InTech eBooks. https://doi.org/10.5772/36102
7. Abou‐Donia, M. B. (2015). Drugs of Abuse. https://doi.org/10.1002/9781118683484.ch26
8. Abramowitz, J. S., & Kalsy, S. A. (2001). Recent developments in the cognitive-behavioral treatment of obsessive-compulsive disorder.. The Behavior Analyst Today. https://doi.org/10.1037/h0099918
9. Agarwal, V., Sitholey, P., & Srivastava, C. (2019). Clinical practice guidelines for the management of dissociative disorders in children and adolescents. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_493_18
10. Aghababaeian, H., & Ahvazi, L. A. (2018). Isn’t it Time to Use Opioid Drugs in Emergency Medical Services?. DOAJ (DOAJ: Directory of Open Access Journals).
11. Ahmed, H. U. (2023). Internet addiction: issues and concerns. Bangladesh Journal of Medicine. https://doi.org/10.3329/bjm.v34i20.66121
12. Aksoy, A., & Ögel, K. (2003). Kendine zarar verme davranişi.
13. Albaladejo, F. (1989). [Neurologic complications of drug addiction. General aspects. Complications caused by cannabis, designer drugs and volatile substances].. PubMed.
14. Albertson, T. E., Chenoweth, J., Colby, D., & Sutter, M. E. (2016). The Changing Drug Culture: Medical and Recreational Marijuana.. PubMed.
15. Albuquerque, A. C. D., Silva, J. R. D., & Silva, J. (2015). The “roundabout Man” Trapped in the “roundabout City” – a Case Report of a Severe Obsessive Compulsive Disorder. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)32056-3
16. Aldweik, A. N., Hussain, K. H., & Alhaj, H. (2023). Can Functional Visual Loss Occur in an Older Adult Patient With a History of Stroke: A Case Report. BJPsych Open. https://doi.org/10.1192/bjo.2023.335
17. Alfonso‐Loeches, S., & Guerri, C. (2011). Molecular and behavioral aspects of the actions of alcohol on the adult and developing brain. Critical Reviews in Clinical Laboratory Sciences. https://doi.org/10.3109/10408363.2011.580567
18. Alghamdi, B., Zrari, M., Elahi, A. M. N., Alwagdani, M., Alghamdi, E. A. S., Moafa, H., Miran, S., Alamoudi, S., Alshahrani, K., Binnwejim, M., & jaafari, M. A. (2018). Substance abuse and its psychiatric effect on adolescence. International Journal of Community Medicine and Public Health. https://doi.org/10.18203/2394-6040.ijcmph20182450
19. Ali, A. A., Shaer, S. S. E., Gad, A. M., & Abu‐Elfotuh, K. (2017). [P1–606]: IMPACT OF PHYSICAL AND MENTAL ACTIVITIES VERSUS PROTEIN MALNUTRITION ASSOCIATED WITH SOCIAL ISOLATION DURING INDUCTION AND PROGRESSION OF ALZHEIMER's DISEASE IN RATS. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2017.06.622
20. Ali, N., Rasheed, A., Tariq, I., Abdullah, F., Sarwar, A., Atta, R., & Qammer, Z. (2018). Adjunct Use of Low Dose Risperidone Verses Adjunct Use of Clonazepam with an SSRI in Treatment of Moderate to Severe Anxiety States; A Comparative Study. National Journal of Health Sciences. https://doi.org/10.21089/njhs.32.0051
21. Alkan, A., Öztorun, H. S., Karcı, E., Ürün, Y., Tuncay, G., Yaşar, A., Çınar, E., Aras, S., Varlı, M., Utkan, G., Demirkazık, A., Akbulut, H., & Şenler, F. Ç. (2020). The Impact of Loneliness and Cancer Diagnosis on Cognitive Impairment in Geriatric Patients. Journal of Oncological Sciences. https://doi.org/10.37047/jos.2019-71889
22. Alloy, L. B., & Abramson, L. Y. (2010). Cyclothymic Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0249
23. Aman, M. G. (1990). Considerations in the use of psychotropic drugs in elderly mentally retarded persons. Journal of Intellectual Disability Research. https://doi.org/10.1111/j.1365-2788.1990.tb01510.x
24. Amihăesei, I. C., & Cojocaru, E. (2014). Main neuroendocrine features, diagnosis and therapeutic possibilities in the chronic fatigue syndrome, an underdiagnosed entity.. PubMed.
25. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
26. Amsterdam, J. V., Pierce, M., & Brink, W. V. D. (2023). Predictors and motives of polydrug use in opioid users. A narrative review. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0000000000000875
27. Anand, K. (2016). Revisiting a dilemma: repetitive pain vs. opioid exposures?. Acta Paediatrica. https://doi.org/10.1111/apa.13442
28. Andrade, C. (2017). Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.17f11567
29. Andréasson, S., Berglund, M., Franck, J., Fridell, M., Håkansson, I., Johansson, B., Lindgren, A., Lindgren, B., Nicklasson, L., Rydberg, U., Salaspuro, M., Thelander, S., & Öjehagen, A. (2001). Behandling av alkohol- och narkotikaproblem: En evidensbaserad kunskapssammanställning.
30. Anghel, L., Boev, M., Stănescu, C., Caramfil, S. M., Luca, L., Mușat, C. L., & Ciubară, A. (2023). Depression in the Diabetic Patient. BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE. https://doi.org/10.18662/brain/14.4/526
31. Anghelescu, A., Magdoiu, A. M., Chirilă, I., Verișezan, O., Opincariu, I., Mureșanu, D. F., & Blesneag, A. (2018). None. Romanian Journal of Neurology. https://doi.org/10.37897/rjn.2018.s
32. Anghelescu, G., Bojescu, A. A., Populeanu, R., Ionică, M., Vlădescu, M., Macovei, R. A., & Caragea, G. (2018). Multiple reactions monitoring for cocaine and ethylbenzoylecgonine to increase the signal/noise ratio in mass spectrometry analysis. Advanced Topics in Optoelectronics, Microelectronics, and Nanotechnologies IX. https://doi.org/10.1117/12.2322569
33. Anisman, H., Merali, Z., Poulter, M. O., & Hayley, S. (2005). Cytokines as a Precipitant of Depressive Illness: Animal and Human Studies. Current Pharmaceutical Design. https://doi.org/10.2174/1381612053381701
34. Antonio, E., & Alfredo, E. (2012). Cocaine Addiction: Changes in Excitatory and Inhibitory Neurotransmission. InTech eBooks. https://doi.org/10.5772/34410
35. Araos, P., Calado, M., Vergara‐Moragues, E., Pedraz, M., Pavón, F. J., & Fonseca, F. R. D. (2014). Adicción a cannabis: bases neurobiológicas y consecuencias médicas.
36. Arendt, M., Rosenberg, R., Fjordback, L., Brandholdt, J., Foldager, L., Sher, L., & Munk-Jørgensen, P. (2007). Testing the self-medication hypothesis of depression and aggression in cannabis dependent subjects. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2007.01.601
37. Arias-Falcón, Y., Reyes-Castellano, A. J., & Pequeño-Rondón, M. M. (2020). Síndrome del niño maltratado. Revista electrónica "Dr. Zoilo E. Marinello Vidaurreta".
38. Arnone, J. M., & Conti, R. P. (2016). Kleine-Levin Syndrome: An Overview and Relevance to Nursing Practice. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20160219-07
39. Arnow, B. A. (2004). Relationships between childhood maltreatment, adult health and psychiatric outcomes, and medical utilization.. PubMed.
40. Arora, A., O'Neill, A., Crome, P., & Martin, F. C. (2014). Clinical Medicine and Substance Misuse. https://doi.org/10.1002/9781118430965.ch5
41. Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium. Gazi Medical Journal.
42. Arredondo-Aldana, K., Mera-Posligua, M. J., & Alencastro, J. A. P. (2021). Trastorno Depresivo Persistente y Trastornos de Ansiedad Generalizada Proveniente de un Estrés Post Traumático Crónico: Presentación de un Caso Clínico. Revista Científica Arbitrada en Investigaciones de la Salud GESTAR. https://doi.org/10.46296/gt.v4i8edesp.0027
43. Ashton, H., Gallagher, P., & Moore, B. P. (2006). The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder. Journal of Psychopharmacology. https://doi.org/10.1177/0269881106061710
44. Ashton, J. C. (2018). Is Cannabis Harmless? Focus on Brain Function. Current Drug Research Reviews. https://doi.org/10.2174/2589977511666180809165622
45. Athanasou, J. A. (2016). Substance Abuse. SensePublishers eBooks. https://doi.org/10.1007/978-94-6300-657-6_17
46. Atumeyi, A. U., Ligom, T. T., & Tivkaa, J. T. (2021). Intake and Abuse of Psychoactive Substances and Its Relative Consequences: A Review. Science Journal of Analytical Chemistry. https://doi.org/10.11648/j.sjac.20210902.12
47. Autor, S. (2002). CÁPSULAS PARA LA VIDA.- ANSIEDAD. Gaceta UNAM (2000-2009).
48. Aveyard, P., & Raw, M. (2012). Improving smoking cessation approaches at the individual level. Tobacco Control. https://doi.org/10.1136/tobaccocontrol-2011-050348
49. Axelson, O. (1996). Where do we go in occupational neuroepidemiology?. Scandinavian Journal of Work Environment & Health. https://doi.org/10.5271/sjweh.114
50. Ayala, L., Gómez‐Revuelta, M., Requena, C. M., Acilu, E. S. D. A. G. D., Olivares, O. P., Ruíz, M. J., Morales, N. N., Martin, M., Zufiaurre, M. L., Hernández, B., Itoiz, A. A., Peña, M., & González‐Pinto, A. (2017). Clozapine: Since the very beginning?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.1402
51. Aytaş, Ö., & Yalvaç, H. D. (2015). Modafinil-Induced Psychosis: A Case Report. Nöro Psikiyatri Arşivi. https://doi.org/10.5152/npa.2015.7160
52. Baat, C. D. (2017). Medicaments and oral healthcare 4. Pharmacotherapy in (frail and care dependent) older people. Nederlands Tijdschrift voor Tandheelkunde. https://doi.org/10.5177/ntvt.2017.05.16244
53. Backer, W. D. (2006). Obstructive Sleep Apnea-Hypopnea Syndrome. KARGER eBooks. https://doi.org/10.1159/000093150
54. Bacos, B. G., Bergamini, V. C., Rodrigues, F. M. F., Marini, D. C., Santos, C. A. D., Viana, B. L. D. A., Vasconcelos, A. P. D., & Rodrigues, F. S. M. (2024). Harm caused by the use of lisdexamfetamine to increase the academic performance of medical students: integrative review. Journal of Medical Residency Review. https://doi.org/10.37497/jmrreview.v3i00.57
55. Bahro, M., Missler, G., & Strnad, J. (1999). [Diagnosis and therapy of alcohol-withdrawal symptoms in the elderly: a case report].. PubMed.
56. Baker, D. L., & Kalivas, P. W. (2005). Sensitization and Relapse. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-852-6_15
57. Baldacchino, A., & Crome, I. (2018). Epidemiological issues in mental health–substance use: a case for a life course approach to chronic disease epidemiology. CRC Press eBooks. https://doi.org/10.1201/b21790-3
58. Baldaçara, L., Ramos, A., & Castaldelli-Maia, J. M. (2023). Managing drug-induced psychosis. International Review of Psychiatry. https://doi.org/10.1080/09540261.2023.2261544
59. Balhara, Y. S., Verma, R., & Mathur, S. (2011). Management of attention-deficit hyperactivity disorder. Journal of Pediatric Neurosciences. https://doi.org/10.4103/1817-1745.84400
60. Barch, D. M., Pagliaccio, D., Luking, K. R., Moran, E. K., & Culbreth, A. J. (2019). Pathways to Motivational Impairments in Psychopathology: Common Versus Unique Elements Across Domains. Nebraska Symposium on Motivation/The Nebraska symposium on motivation. https://doi.org/10.1007/978-3-030-27473-3_5
61. Bari, A., Robbins, T. W., & Dalley, J. W. (2010). Impulsivity. Neuromethods. https://doi.org/10.1007/978-1-60761-934-5_14
62. Barker, R. A., & Redfern, C. (2019). Parkinson’s Disease, Religious Belief and Spirituality. Cambridge University Press eBooks. https://doi.org/10.1017/9781316014165.011
63. Barkin, R. L. (2007). Zolpidem Extended-Release: A Single Insomnia Treatment Option for Sleep Induction and Sleep Maintenance Symptoms. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0b013e31804c7292
64. Baronia, R. B. (2015). Oral Hydrocodone Induced Acute Psychosis in an Adult Male: A CaseReport.. Journal of Clinical Case Reports. https://doi.org/10.4172/2165-7920.1000535
65. Barrio, P., Seeman, M. V., & González-Rodríguez, A. (2021). Alcohol and Psychosis: A Narrative Review of the Prevalence, Clinical Manifestations, and Management of Alcohol-related Psychotic Symptoms. Current Psychiatry Research and Reviews. https://doi.org/10.2174/2666082217666210602111739
66. Bartels, K., & Schacht, J. P. (2021). Cocaine-Positive Patients Undergoing Elective Surgery: From Avoiding Case Cancellations to Treating Substance Use Disorders. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000004969
67. Barton, S., Karner, C., Salih, F., Baldwin, D. S., & Edwards, S. J. (2014). Clinical effectiveness of interventions for treatment-resistant anxiety in older people: a systematic review. Health Technology Assessment. https://doi.org/10.3310/hta18500
68. Batta, A., & Farid, B. (2011). Addiction in Adolescents ---- A Current Trend.
69. Baving, L., & Olbrich, H. M. (1996). Alcoholism and Depression. European Addiction Research. https://doi.org/10.1159/000259099
70. Becker, W. C., Frank, J. W., Edmond, S. N., & Starrels, J. L. (2023). When harms outweigh benefits of long‐term opioid therapy for pain: Need for a new diagnostic entity, research and improved treatments. Addiction. https://doi.org/10.1111/add.16348
71. Beebe, D. K., & Walley, E. (1991). Substance abuse: the designer drugs.. PubMed.
72. Beek, N. V. (2003). Vulnerability factors in panic disorder patients and their first-degree relatives : inquiries into carbon dioxide vulnerability, anxiety sensitivity, and respiratory pathology. https://doi.org/10.26481/dis.20031017nb
73. Bell, D. S. (1973). The Experimental Reproduction of Amphetamine Psychosis. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1973.04200010020003
74. Belmaker, R. H. (2007). Treatment of Bipolar Depression. New England Journal of Medicine. https://doi.org/10.1056/nejme078042
75. Benbow, S. (2018). Electricity, magnetism and mood. CRC Press eBooks. https://doi.org/10.1201/9781315382913-6
76. Benowitz, N. L. (1993). Clinical Pharmacology and Toxicology of Cocaine. Pharmacology & Toxicology. https://doi.org/10.1111/j.1600-0773.1993.tb01331.x
77. Berastegui, C., Monfort, E., & Boudin, B. (2017). Vocally disruptive behaviors management in older people with dementia. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2017.0657
78. Bereda, G. (2023). Seizures Are the Main Sign of Epilepsy: Stages of Seizures. Pathology and Laboratory Medicine. https://doi.org/10.11648/j.plm.20230701.11
79. Bernard, S., Enayati, A., Binstock, T., Roger, H., Redwood, L., & McGinnis, W. (2004). Autism: A Unique Type of Mercury Poisoning.
80. Bersselaar, L. R. V. D., Hoeven, J. G. V. D., & Jong, B. D. (2020). Feeling Death, Being Alive: 4-Methylethcathinone/Pentedrone Addiction and 3-Methoxyphencyclidine Intoxication. Addictive Disorders & Their Treatment. https://doi.org/10.1097/adt.0000000000000214
81. Bertodo, T. D. S., Gross, M. S., & Maldaner, E. B. (2018). TRANSTORNOS BIPOLAR E DEPRESSIVO: UMA REVISÃO DOS ASPECTOS CONCEITUAIS.
82. Bibi, E. S. D. M. (2021). AN OVERVIEW OF POST WAR SOCIAL PROBLEMS IN SYRIA. Pakistan Journal of International Affairs. https://doi.org/10.52337/pjia.v2i2.63
83. Bitnun, A., & Richardson, S. E. (2015). Childhood Encephalitis in Canada in 2015. Canadian Journal of Infectious Diseases and Medical Microbiology. https://doi.org/10.1155/2015/947602
84. Black, D. W. (2007). Compulsive Buying Disorder: <i>A Review of the Evidence</i>. CNS Spectrums. https://doi.org/10.1017/s1092852900020630
85. Blagojević-Damašek, N., Frencl, M., Pereković, V., Cavajda, Z., & Kovacek, M. (2012). Locus of Control, Social Support and Alcoholism. Alcoholism and psychiatry research Journal on psychiatric research and addictions.
86. Blanco, C., & Bernardi, S. (2014). Gambling Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg62
87. Blay, S. L. (2011). A Case of Major Depressive Disorder and Symptoms of Polycystic Ovary Syndrome Responding to Escitalopram. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01183
88. Boboc, C., Isac, A., & Lupu, V. (2017). P291 Ethiological particuliarities in acute psychotic disorder in an adolescent – case report. https://doi.org/10.1136/archdischild-2017-313273.379
89. Bolton, D., Hailu, T., & Porucznik, C. A. (2023). Resolution of stuttering during ketamine treatment: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-023-04158-8
90. Bolton, E., Holohan, D. R., King, L. A., & King, D. W. (2004). Acute and Post-Traumatic Stress Disorder. Routledge eBooks. https://doi.org/10.4324/9780203336960-13
91. Bordini, L., Riboldi, L., & Ferrario, M. (2013). [Psychotropic substances and driving].. PubMed.
92. Borovac, A. (2018). Zdravstvena njega bolesnika - ovisnika o psihoaktivnim tvarima.
93. Borowski, M. (2013). Addiction as a Disease. European Researcher. https://doi.org/10.13187/er.2013.55.1945
94. Bosch, W. V. D., & Weel‐Baumgarten, E. V. (2003). [Depression: longer-lasting episode not an automatic indication for referral].. PubMed.
95. Bostwick, J. R., & Demehri, A. (2017). Pills to Powder: An Updated Clinician's Reference for Crushable Psychotropics. Current psychiatry.
96. Boughton, B. J. (1991). Hepatic and portal vein-thrombosis.. BMJ. https://doi.org/10.1136/bmj.302.6770.192
97. Bouritius, E. M., Neven, A. K., & Blom, J. D. (2015). [Alcohol hallucinosis].. PubMed.
98. Boylan, K., & Eppel, A. (2008). The severe mood dysregulation phenotype: case description of a female adolescent.. PubMed.
99. Branković, S. (2015). Boredom, dopamine, and the thrill of psychosis: psychiatry in a new key.. PubMed.
100. Bransfield, R., Embers, M., & Dwork, A. (2023). A Fatal Case of Late Stage Lyme Borreliosis and Substance Abuse. Journal of Affective Disorders Reports. https://doi.org/10.1016/j.jadr.2023.100525
101. Brashear, A., Sweadner, K. J., Cook, J., Swoboda, K. J., & Ozelius, L. J. (2014). ATP1A3-Related Neurologic Disorders. University of Washington, Seattle eBooks.
102. Breuer, L., Kasper, B. S., Schwarze, B., Gschossmann, J. M., Kornhuber, J., & Müller, H. (2015). “Herbal seizures” – atypical symptoms after ibogaine intoxication: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-015-0731-4
103. Brock, K. A., Nguyen, B., Liu, N., Watkins, M., & Reutzel, T. J. (2005). The Use of Antidepressants in School-Age Children. The Journal of School Nursing. https://doi.org/10.1177/10598405050210060301
104. Brock, K. A., Nguyen, B., Liu, N., Watkins, M., & Reutzel, T. J. (2005). The Use of Antidepressants in School-Age Children. The Journal of School Nursing. https://doi.org/10.1622/1059-8405(2005)021[0318:tuoais]2.0.co;2
105. Brodrick, J. E., & Mitchell, B. G. (2015). Hallucinogen Persisting Perception Disorder and Risk of Suicide. Journal of Pharmacy Practice. https://doi.org/10.1177/0897190014566314
106. Brody, D. L. (2014). Attention Deficit. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199383863.003.0008
107. Brody, D. L. (2014). Balance Problems. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199383863.003.0013
108. Brody, D. L. (2014). Executive Dysfunction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199383863.003.0018
109. Bruch, S. (2013). Cultural concerns and issues in emergency psychiatry. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139088077.041
110. Bruin, E. I. D., Meppelink, R., & Bögels, S. M. (2020). Mindfulness in attention deficit hyperactivity disorder. Routledge eBooks. https://doi.org/10.4324/9781315563862-7
111. Brust, J. C. (2002). Neurologic Complications of Substance Abuse. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/00126334-200210012-00002
112. Brust, J. C. (2002). Seizures and Illicit Drug Use. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-094-0_11
113. BS, A. H., & BA, M. F. (2018). Glossary. https://doi.org/10.1002/9781119449737.gloss
114. Buckley, P. (2006). Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness.. PubMed.
115. Buckley, P., & Foster, A. (2014). Schizophrenia. https://doi.org/10.1007/978-3-7091-0715-7_4
116. Budak, E. (2015). Alkol ve Madde Etkisi Altinda Araç Kullanimi ile İlişkili Psikolojik Faktörler Driving under the Influence of Alcohol and Substance and Related Psychological Factors.
117. Budak, E., & Taymur, İ. (2015). Psychological Factors related with Driving under the Influence of Alcohol and Substance Use. DergiPark (Istanbul University). https://doi.org/10.18863/pskguncel.133504
118. Budson, A. E., & O’Connor, M. K. (2021). How to manage emotional problems. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780190098124.003.0008
119. Bullock, R., & Teasdale, G. (1990). ABC of major trauma. Head injuries--II.. BMJ. https://doi.org/10.1136/bmj.300.6739.1576
120. Buoli, M., Serati, M., & Cahn, W. (2015). Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.2016.1135735
121. Burgić-Radmanović, M. (2011). Affective disorders in childhood and adolescence. Acta Medica Academica. https://doi.org/10.5644/ama.v40i1.103
122. Burkart, J., Jong, M. C., Ilenkyo, L., Verwer, C., Weber, S., Keller, T., & Klement, P. (2017). P172 Results of a randomised controlled trial with a homeopathic complex medicinal product in children with sleep disorders and restlessness. https://doi.org/10.1136/archdischild-2017-313273.260
123. Burkhart, P. W. M. K. K. (2014). Drugs Highly Associated with Infusion Reactions Reported using Two Different Data-mining Methodologies. Journal of Blood Disorders & Transfusion. https://doi.org/10.4172/2155-9864.1000195
124. Buss, T., & Modlińska, A. (2004). [Cancer-related fatigue. II. Causes and management of the problem]..
125. Bustos, R., & esmirna, M. (2012). CRITERIOS DE ANALIZABILIDAD EN EL PACIENTE FRONTERIZO.
126. Bénony, H., Bénony-Viodé, C., & Dumas, J. (2012). Le trouble hyperkinétique ou déficit de l'attention/hyperactivité. Le point sur... Psychologie.
127. Bénony, H., Bénony-Viodé, C., & Dumas, J. (2012). Les troubles de l'humeur. Le point sur... Psychologie.
128. Bürk, K., Strelczyk, A., & Oertel, W. H. (2012). Intermittent Tunnel Vision in a Patient With Multiple Drug Abuse History. Movement Disorders. https://doi.org/10.1891/9781617050589.0090
129. Cabrejo-Mendoza, H. J., & Albornoz-Muñoz, D. P. (2023). Trastorno de Acumulación: A propósito de un caso. Revista de Neuro-Psiquiatría. https://doi.org/10.20453/rnp.v86i1.4469
130. Caldwell, J., & Sever, P. S. (1974). The biochemical pharmacology of abused drugs. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt1974164625
131. Campos, R. C. (2017). Striatum, Dopamine and Automatism in Cocaine Addiction and Relapse : Pharmacological and Behavioral Investigation.
132. Capaldi, D. M., & Kim, H. K. (2014). Comorbidity of Depression and Conduct Disorder. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780199797004.013.015
133. Carlin, A., & O'Malley, S. (1996). Neuropsychological Consequences of Drug Abuse. https://doi.org/10.1093/oso/9780195090734.003.0019
134. Castellanos, G., Escobar, A. P., & González, B. G. (2006). Estrés y conducta adictiva. DELETED.
135. Ceraudo, G., Vannucchi, G., Perugi, G., & Dell’Osso, L. (2012). [Adult ADHD: clinical aspects and therapeutic implications].. PubMed. https://doi.org/10.1708/1178.13052
136. Cerón-Apipilhuasco, A., Loría-Castellanos, J., & Gómez-Bañuelos, L. V. (2023). Intoxicaciones delictivas. Anales Médicos de la Asociación Médica del Centro Médico ABC. https://doi.org/10.24875/amh.m23000027
137. Chabris, C. F., Laibson, D., & Schuldt, J. P. (2008). intertemporal choice. The New Palgrave Dictionary of Economics. https://doi.org/10.1057/9780230226203.0843
138. Chakraborty, K., & Bhide, A. (2020). General Principles for Psychotherapeutic Interventions in Children and Adolescents. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_811_19
139. Challacombe, F., & Wroe, A. L. (2013). A hidden problem: consequences of the misdiagnosis of perinatal obsessive–compulsive disorder. British Journal of General Practice. https://doi.org/10.3399/bjgp13x667376
140. Chang, Y.-S., Anderson, N., Long, K., Murphy, C., McMahan, V., Rodda, L. N., Kral, A. H., & Coffin, P. O. (2025). Refining cause of death attribution among opioid, opioid‐stimulant and stimulant acute toxicity deaths. Addiction. https://doi.org/10.1111/add.70190
141. Chaouloff, F., Dubreucq, S., Matias, I., & Marsicano, G. (2013). Physical activity feel-good effect:The role of endocannabinoids. Routledge eBooks. https://doi.org/10.4324/9780203132678-12
142. Chauca, G. C., Expósito, L. C., & Lobato, P. (2017). Electroconvulsive therapy as an effective alternative in depressive disorder. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.703
143. Chaudhury, S., Tikka, S. K., & Bakhla, A. K. (2016). Impact of Substance Use Disorder on Presentation of Schizophrenia. Dual Diagnosis Open Access. https://doi.org/10.21767/2472-5048.100007
144. Cheung, K., Patch, K., Earp, B. D., & Yaden, D. B. (2023). Psychedelics, Meaningfulness, and the “Proper Scope” of Medicine: Continuing the Conversation. Cambridge Quarterly of Healthcare Ethics. https://doi.org/10.1017/s0963180123000270
145. Chicoș, O., Perri, D., Capriș, L., Iliescu, A. I. B., & Kantor, C. (2019). Social-Cultural Influences and Personality Disorders Favoring Drug Consumption. BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE. https://doi.org/10.70594/brain/v10.s1/3
146. Ciraulo, D. M., & Ciraulo, D. A. (2008). Benzodiazepines <i>Misuse, Abuse, and Dependence</i>. https://doi.org/10.1093/oso/9780195300550.003.0019
147. Clark, D. A., & Purdon, C. (2003). Cognitive theory and therapy of obsessions and compulsions. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139087094.006
148. Clavenna, A., & Bonati, M. (2017). Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2017.1389894
149. Claxton, K. L., Chen, J. J., & Swope, D. (2007). Drug-Induced Movement Disorders. Journal of Pharmacy Practice. https://doi.org/10.1177/0897190007310514
150. Clay, S., Allen, J. V., & Parran, T. (2008). A Review of Addiction. Postgraduate Medicine. https://doi.org/10.3810/pgm.2008.07.1802
151. Coelho, C. M. M., Santos, G. X. C., Magano, S., Mota, D., Ferreira, S., Araújo, A. I., Cabaços, C., & Macedo, A. (2019). Treatment of Depersonalization-derealization Disorder With Transcranial Magnetic Stimulation. https://doi.org/10.26226/morressier.5d1a037457558b317a1404e8
152. Cohen, J. A., Mowchun, J. J., Lawson, V. H., & Robbins, N. M. (2016). A 19-Year-Old Male with Stiffness and Weakness After Waking. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190491901.003.0026
153. Cohen, R., Pereira, I., Garrido, M. M., Ferreira, B., & Sousa, M. D. C. (2023). Suicidal ideation in older people, a public health matter. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1786
154. Colado, M. I., O’Shea, E., & Green, A. R. (2007). MDMA and Other “Club Drugs”. https://doi.org/10.1002/9780470101001.hcn039
155. Colán, T. C., Gálvez, G. A., & Zevallos, D. C. (2013). Síntomas psiquiátricos e insulinoma: reporte de caso Psychiatric symptoms and insulinoma: a case report.
156. Coman, H., Cozman, D., Buciuta, A., & Nemeş, B. (2019). Managementul tratamentului tulburărilor cauzate de consumul de substanţe psihoactive. Psihiatru ro.
157. Coman, H., Cozman, D., Buciuta, A., & Nemeş, B. (2019). Treatment management of psychoactive substance use disorders. Psihiatru ro. https://doi.org/10.26416/psih.59.4.2019.2604
158. Compton, D. M., Dewey, W. L., & Martin, B. R. (1990). Canabis Dependence and Tolerance Production. Advances in Alcohol & Substance Abuse. https://doi.org/10.1300/j251v09n01_08
159. Compton, M. T., & Broussard, B. (2010). Psychosocial Treatments for Early Psychosis. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195372496.003.0016
160. Conaglen, H. M., & Conaglen, J. V. (2013). Drug-induced sexual dysfunction in men and women. Australian Prescriber. https://doi.org/10.18773/austprescr.2013.021
161. Conde, I. L., Fernández‐Montalvo, J., Ustárroz, J. T., González, N. L., & López‐Goñi, J. J. (2010). Rendimiento neuropsicológico en la adicción a la cocaína: una revisión crítica. Revista de Neurología. https://doi.org/10.33588/rn.5107.2010395
162. Connor, J. P., Stjepanović, D., Budney, A. J., Foll, B. L., & Hall, W. (2021). Clinical management of cannabis withdrawal. Addiction. https://doi.org/10.1111/add.15743
163. Conway, K. P., Montoya, I. D., & Compton, W. M. (2007). Lifetime Psychiatric Comorbidity of Illicit Drug Use Disorders. The Psychiatric times.
164. Copeland, J., Clement, N., & Swift, W. (2014). Cannabis use, harms and the management of cannabis use disorder. Neuropsychiatry. https://doi.org/10.2217/npy.13.90
165. Coronado, L. M. Q., Florez, D. A. C., & Tarazona, M. C. L. (2017). Prevalencia depresión en estudiantes universitarios Bucaramanga 2017.
166. Correia‐Melo, F. S., Silva, S. S., Araújo-de-Freitas, L., & Quarantini, L. C. (2017). S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression. Brazilian Journal of Psychiatry. https://doi.org/10.1590/1516-4446-2016-2070
167. Correll, C. U., Kratochvil, C. J., & March, J. S. (2011). Developments in Pediatric Psychopharmacology. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.11r07064
168. Corrêa, C. R. G. L. (2013). Attention – Deficit Hyperactivity Disorder (ADHD) in Psychiatry and Psychoanalysis. InTech eBooks. https://doi.org/10.5772/52880
169. Covington, H. E., & Miczek, K. A. (2010). Binge Drug Taking. Neuromethods. https://doi.org/10.1007/978-1-60761-934-5_15
170. Crocker, C. E., Carter, A., Emsley, J. G., Magee, K., Atkinson, P., & Tibbo, P. G. (2021). When Cannabis Use Goes Wrong: Mental Health Side Effects of Cannabis Use That Present to Emergency Services. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2021.640222
171. Crome, I., & Myton, T. (2004). Pharmacotherapy in dual diagnosis. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.10.6.413
172. Cruickshank, C., & Dyer, K. R. (2009). A review of the clinical pharmacology of methamphetamine. Addiction. https://doi.org/10.1111/j.1360-0443.2009.02564.x
173. Cuevas, M. J. S. (2005). EL TRASTORNO POR DÉFICIT DE ATENCIÓN CON HIPERACTIVIDAD (314.01) Y SU INCIDENCIA EN EL MEDIO ESCOLAR, FAMILIAR Y SOCIAL EN EL CAMPO DE GIBRALTAR. Almoraima:  revista de estudios campogibraltareños.
174. Cummings, P. M., Trelka, D. P., & Springer, K. M. (2013). Poisoning. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511920905.007
175. Dailey, J., & Clementz, G. L. (1988). Psychotropic effects of caffeine.. PubMed.
176. Daley, D. C., & Douaihy, A. (2019). Effects of Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0004
177. Daley, D. C., & Douaihy, A. (2019). Managing Cravings and Urges to Use Substances. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0009
178. Daley, D. C., & Douaihy, A. (2019). Medications for Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0006
179. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
180. Daley, D. C., & Douaihy, A. (2019). Understanding Substance Use Problems. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0002
181. Darriba, H. B. (2023). A complex polymorphous psychosis or a cycloid psychosis with a different onset?. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.2246
182. Das, C., & Joseph, S. (2005). Falls in elderly.. PubMed.
183. Dastidar, P. G. (2024). Quality Of Life and Functional Impairment in Adults withOcdReview Of Literature. African Journal of Biomedical Research. https://doi.org/10.53555/ajbr.v27i4s.4585
184. David, M., Lincoln, I., Anne, W., & Mutiso, V. (2011). Epidemiological Patterns of Anxiety Disorders in Kenya. InTech eBooks. https://doi.org/10.5772/19184
185. Davidson, M., Rashidi, N., Hossain, M. K., Raza, A., Nurgali, K., & Apostolopoulos, V. (2023). Tryptophan and Substance Abuse: Mechanisms and Impact. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032737
186. Davies, D. (2023). Defining Alcoholism. Routledge eBooks. https://doi.org/10.4324/9781032616988-5
187. Davies, J. B., Saunders, W., & Helfgott, S. (2018). What is addiction?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198797746.003.0001
188. Davis, K. M., Chu, L. E., & Murdock, K. W. (2023). Burnout. CRC Press eBooks. https://doi.org/10.1201/b22810-10
189. De, H. (1982). Methadone and heroin during pregnancy: a review of behavioral effects in human and animal offspring.. PubMed.
190. Delanerolle, G., Shetty, S., Raymont, V., Hapangama, D. K., Haque, N., Shi, J. Q., Ayis, S., Shetty, A., & Phiri, P. (2021). None. LOJ Medical Sciences. https://doi.org/10.32474/lojms.5.5
191. Delcea, C. (2019). Orgasmic disorder in women. International Journal of Advanced Studies in Sexology. https://doi.org/10.46388/ijass.2019.12.11.122
192. Delcea, C. (2019). Sexual deviances. International Journal of Advanced Studies in Sexology. https://doi.org/10.46388/ijass.2019.12.119
193. Delgado, S., Mosquera, N., Herrera, J., Espín, P., & Aparicio, C. X. P. D. (2021). Daños neurológicos en adolescentes por consumo de cocaína. RECIMUNDO. https://doi.org/10.26820/recimundo/5.(suple1).oct.2021.125-130
194. Delgado, S., Wassenaar, E., & Strawn, J. R. (2011). Does Your Patient Have a Psychiatric Illness or Nonverbal Learning Disorder? Clinical Clues Help Differentiate Overlapping Symptoms and Syndromes. Current psychiatry.
195. DeLuca, G. C., & Bartleson, J. D. (2010). When and How to Investigate the Patient with Headache. Seminars in Neurology. https://doi.org/10.1055/s-0030-1249221
196. Demaret, I., Lemaître, A., & Ansseau, M. (2013). [Heroin].. PubMed.
197. Demb, H. B., Papola, P., Rosenberg, R. L., & Plum, E. (1998). A Typical Children Followed-Up in Adolescence. Clinical Child Psychology and Psychiatry. https://doi.org/10.1177/1359104598032011
198. Denbeaux, M., Camoni, S. A., Beroth, B., Chrisner, M., Loyer, C., & Taylor, P. W. (2012). Drug Abuse: An Exploration of the Government's Use of Mefloquine at Guantánamo. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.2002902
199. Derman, E., Whitesman, S., Dreyer, M., Patel, D., Nossel, C., & Schwellnus, M. (2010). Healthy lifestyle interventions in general practice: Part 12: Lifestyle and depression. South African Family Practice. https://doi.org/10.1080/20786204.2010.10873989
200. Dervaux, A. (2013). En quoi et comment le cannabis peut-il être toxique pour le cerveau ?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2013.09.004
201. Dhillon, R. S. (2013). The Potential for Abuse: Addiction. Berkeley Scientific Journal. https://doi.org/10.5070/bs3181020649
202. Dhingra, L., Ahmed, E., Shin, J. G., Scharaga, E., & Magun, M. (2015). Cognitive Effects and Sedation. Pain Medicine. https://doi.org/10.1111/pme.12912
203. Dieterich, C. A., Snyder, N. D., & Villani, C. J. (2016). A legal study of children with emotional disturbance and mental health needs and implications for practice.. The Journal of Law of Education.
204. DiFranza, J. R., Wellman, R. J., Mermelstein, R. J., Pbert, L., Klein, J. D., Sargent, J. D., Ahluwalia, J. S., Lando, H. A., Ossip, D. J., Wilson, K. M., Balk, S. J., Hipple, B., Tanski, S. E., Prokhorov, A. V., Best, D., & Winickoff, J. P. (2011). The Natural History and Diagnosis of Nicotine Addiction. Current Pediatric Reviews. https://doi.org/10.2174/157339611795735648
205. DiMartini, A. (2007). Natural history of alcohol use disorders in liver transplant patients. Liver Transplantation. https://doi.org/10.1002/lt.21342
206. Dobrescu, I., Rad, F., Anghel, G. C., Stancu, M., & Buică, A. (2017). P288 Somatic complaints in anxiety disorders. https://doi.org/10.1136/archdischild-2017-313273.376
207. Dobry, Y., Braquehais, M. D., & Sher, L. (2013). Bullying, psychiatric pathology and suicidal behavior. International Journal of Adolescent Medicine and Health. https://doi.org/10.1515/ijamh-2013-0065
208. Dolenc, T. J. (2015). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214883.003.0044
209. Dongier, M. (2003). What treatment options exist for alcohol abuse?. Journal of Psychiatry and Neuroscience. https://doi.org/10.1139/jpn.0307
210. Douglas, K. S. (2015). Addiction and Violence Risk. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp432
211. Drogin, E. Y., Dattilio, F. M., Sadoff, R. L., & Gutheil, T. G. (2011). Appendix A: Scientific Glossary. https://doi.org/10.1002/9781118093399.app1
212. Dubovsky, S. (2015). Prenatal Cocaine Is Bad for the Baby's Brain. Journal watch. https://doi.org/10.1056/nejm-jw.na37566
213. DuPont, R. L. (1990). A practical approach to benzodiazepine discontinuation. Journal of Psychiatric Research. https://doi.org/10.1016/0022-3956(90)90039-s
214. Dydak, K., Śliwińska‐Mossoń, M., & Milnerowicz, H. (2015). [Psilocybin - public available psychodysleptic].. PubMed.
215. Dydyk, A. M., Jain, N., & Gupta, M. (2021). Opioid Use Disorder.
216. Dåderman, A. M., & Lidberg, L. (1999). [Rohypnol should be classified as a narcotic].. PubMed.
217. Díez‐Tejedor, E., Tejada, J. H., & Frank, A. (1989). [Neurologic complications caused by use of cocaine, amphetamines and sympathomimetics].. PubMed.
218. d’Andrea, G., Marco, O. D., Semeraro, F. M., Carullo, R., Sensi, S. L., Pettorruso, M., & Martinotti, G. (2023). Intranasal esketamine as tool for rapid cycling bipolar disorder: A case report of successful mood stabilization. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2023.100188
219. D’cruz, M., Andrade, C., & Rao, T. S. (2020). The Expression of Intimacy and Sexuality in Persons With Dementia. Journal of Psychosexual Health. https://doi.org/10.1177/2631831820972859
220. D’Souza, D. C. (2023). Cannabis, cannabinoids and psychosis: a balanced view. World Psychiatry. https://doi.org/10.1002/wps.21075
221. Ebenezer, I. S. (2015). Affective Disorders 2: Bipolar Disorder. https://doi.org/10.1002/9781118385777.ch7
222. Ebenezer, I. S. (2015). Drug Abuse and Addiction. https://doi.org/10.1002/9781118385777.ch11
223. Echeburúa, E., & Gargallo, P. D. C. (1994). Adicciones psicológicas: Más allá de la Metáfora. Clínica y Salud.
224. Eckert, W. G. (1982). Physician crimes and criminals. American Journal of Forensic Medicine & Pathology. https://doi.org/10.1097/00000433-198209000-00007
225. Efeoğlu, P., Dağlıoğlu, N., Hilal, A., & Gülmen, M. K. (2013). Drugs Used in Sexual Assaults: Features and Toxicological Investigations. DergiPark (Istanbul University).
226. El-Hamady, M. M., El-Sayed, H., Bakry, S. E., & Youniss, M. (2020). Prevalence of Anxiety Disorders in Substance Related Disorders. Benha Journal of Applied Sciences. https://doi.org/10.21608/bjas.2020.137193
227. Elhassan, N. M., Al‐Salihy, Z., Bushra, M., Sanabel, A.-A., Albobaly, Y., Eltorki, Y., & Alabdulla, M. (2018). Use of Benzodiazepines and Hypnotic Medications in Psychiatry Older Adult Outpatients. International Journal of Case Reports. https://doi.org/10.28933/ijcr-2018-11-1006
228. Elkind, A. H. (1989). Drug Abuse in Headache Patients. Clinical Journal of Pain. https://doi.org/10.1097/00002508-198903000-00019
229. Ertem, D. H., Maner, F., & Köksal, A. (2013). Text messaging as a new compulsive behavior in a patient with <scp>P</scp>arkinson's disease. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.12015
230. Escayola, E. N., Caballero, J. M. M.-Q., & Valencia, B. C. (2014). Valoración médico forense de muerte en custodia por delirium agitado. A propósito de un caso.
231. Eschalier, A., Fialip, J., Aumaître, O., Maradeix, B., Dordain, G., & Lavarenne, J. (1987). Benzodiazepine withdrawal seizures: analysis of 48 case reports.. PubMed.
232. Espay, A. J., Chaná, P., González-Usigli, H., & LaFaver, K. (2015). Psychostimulants and movement disorders.
233. Espinosa‐Jovel, C., & Sobrino, F. (2017). Caffeine and headache: specific remarks. Neurología (English Edition). https://doi.org/10.1016/j.nrleng.2014.12.022
234. Espinoza, H., & Vicente, J. (2015). Trastorno por ansiedad en paciente de 46 años de escolarización medio con tratamiento psicoterapéutico en modelo psicológico cognitivo conductual..
235. Estroff, T. W., & Gold, M. S. (2022). Medical and Psychiatric Complications of Cocaine Abuse With Possible Points of Pharmacological Treatment. Routledge eBooks. https://doi.org/10.4324/9781003282822-6
236. Ettensohn, M. F., Markey, S. M., & Levine, S. P. (2018). Considering Ketamine for Treatment of Comorbid Pain, Depression, and Substance Use Disorders. Psychiatric Annals. https://doi.org/10.3928/00485713-20180312-02
237. Evers, M. M., & Marin, D. B. (2002). Mood disorders. Effective management of major depressive disorder in the geriatric patient.. PubMed.
238. Evrard, S. G. (2010). [Diagnostic criteria for fetal alcohol syndrome and fetal alcohol spectrum disorders].. PubMed. https://doi.org/10.1590/s0325-00752010000100011
239. Faeder, M., Hale, E., Hedayati, D., Israel, A., Moschenross, D., Peterson, M., Peterson, R., Piechowicz, M., Punzi, J., & Gopalan, P. (2023). Preventing and treating delirium in clinical settings for older adults. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253231198462
240. Falk, A., Joseph, R., Smith, S., & Wilk, A. (2023). Mood and Anxiety Disorders: Major Depressive Disorder.. PubMed.
241. Fama, J. M., & Wilhelm, S. (2010). Obsessions. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0616
242. Farnsworth, M. G. (1990). Benzodiazepine abuse and dependence: misconceptions and facts.. PubMed.
243. Farrell, B., Hughes, L., Neutel, I., & Babcock, K. (2003). Facilitating the Process of Medication Re-evaluation and Withdrawal in the Long-Term Institutionalized Population: The Example of Cisapride. The Canadian Journal of Hospital Pharmacy. https://doi.org/10.4212/cjhp.v56i1.407
244. Fatigoni, S., Fumi, G., & Roila, F. (2015). [Cancer-related fatigue].. PubMed. https://doi.org/10.1701/1740.18954
245. Fava, G. A., Benasi, G., & Cosci, F. (2017). The Potential Role of Iatrogenic Comorbidity in the Interaction between Pharmacotherapy and Psychotherapy in Anxiety Disorders. Verhaltenstherapie. https://doi.org/10.1159/000460826
246. Favrat, B., Guessous, I., Gonthier, A., & Cornuz, J. (2015). [Prolonged or chronic fatigue of unknown origin].. PubMed.
247. Favrat, B., Guessous, I., Gonthier, A., & Cornuz, J. (2015). Anhaltende bzw. chronische Müdigkeit unbekannter Ätiologie. Swiss Medical Forum ‒ Schweizerisches Medizin-Forum. https://doi.org/10.4414/smf.2015.02260
248. Fazel, M., Reed, R. V., & Goldring, L. (2012). Post-traumatic stress disorder. BMJ. https://doi.org/10.1136/bmj.e3790
249. Ferrara, P. (2014). Child abuse and neglect: psychiatric and neuro-biological consequences. The Italian Journal of Pediatrics/Italian journal of pediatrics. https://doi.org/10.1186/1824-7288-40-s1-a32
250. Fessas, P., & Duret, A. (2018). Question 1: Is there a role for the ketogenic diet in refractory status epilepticus?. Archives of Disease in Childhood. https://doi.org/10.1136/archdischild-2018-315755
251. Filippis, S. D., Salvatori, E., Coloprisco, G., & Martelletti, P. (2006). [Chronic daily headache: management and rehabilitation].. PubMed.
252. Fine, L., Dubrovsky, B., & Spielman, A. J. (2011). Insomnia. BENTHAM SCIENCE PUBLISHERS eBooks. https://doi.org/10.2174/978160805153311101010137
253. Fingerhood, M. (2020). Sedatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0005
254. Fink, M. (2010). Depressive Mood Disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195365740.003.0009
255. Fink, M. (2010). Movement Disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195365740.003.0011
256. Finsterer, J., & Zarrouk‐Mahjoub, S. (2013). Fatigue in Healthy and Diseased Individuals. American Journal of Hospice and Palliative Medicine®. https://doi.org/10.1177/1049909113494748
257. Fipps, D. C., & Sinha, S. (2023). Substance Use Disorders and Sleep. Psychiatric Annals. https://doi.org/10.3928/00485713-20231019-01
258. Fisher, A. D., Bandini, E., Casale, H., & Maggi, M. (2011). Paraphilic Disorders: Diagnosis and Treatment. https://doi.org/10.1002/9781119963820.ch8
259. Flores, C. (2010). FACTORES QUE INFLUYEN EN LA ADICCIÓN ADOLESCENTE. Contribuciones a las Ciencias Sociales.
260. Fontalba-Navas, A., & Caparros-del-Moral, I. (2015). New Approaches to Psychotic Agitation: Staccato Loxapine. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)30809-9
261. Foo, Y.-C., Tam, C. L., Ehsan, S. D., & Cheah, J. (2012). Impacts of Drug Use on Memory. AUSTRALIAN JOURNAL OF BASIC AND APPLIED SCIENCES.
262. Forcén, F. E. (2015). Akathisia: Is Restlessness a Primary Condition or an Adverse Drug Effect? Keep a Discerning Eye out for This Adverse Effect of Antipsychotics and Other Drugs. Current psychiatry.
263. Forray, A. (2016). Substance use during pregnancy. F1000Research. https://doi.org/10.12688/f1000research.7645.1
264. Fowler, R. C. (1986). San Diego Suicide Study. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1986.01800100056008
265. Fraga, J. A. G., & Conesa, P. M. (2006). Valoración del enfermo drogodependiente en los Servicios de Urgencias. Adicciones.
266. Franjić, S. (2023). Child Abuse and Neglect is a Serious Problem in Every Society. Deleted Journal. https://doi.org/10.33140/jre.01.01.03
267. Franklin, J. (1995). Addiction Medicine. JAMA. https://doi.org/10.1001/jama.1995.03520450026012
268. Frazer, D. W., Hinrichsen, G. A., & Jongsma, A. E. (1998). The Older Adult Psychotherapy Treatment Planner.
269. Frean, J., Jong, G. D., & Albrecht, R. (2008). Imaginary bugs, real distress: delusional parasitosis.. PubMed.
270. Fregonese, L., Silvestri, M., Sabatini, F., Defilippi, A., & Rossi, G. A. (2001). Severe and near-fatal asthma in children and adolescents.. PubMed.
271. Friedel, B. (1991). ARZNEIMITTEL UND STRASSENVERKEHR. Arzt und Auto.
272. Fuente, J. R. D. L., & Kershenobich, D. (1992). I. El alcoholismo como problema médico. Revista de la Facultad de Medicina.
273. Funk, S. (2013). [Pharmacological treatment in alcohol-, drug- and benzodiazepine-dependent patients - the significance of trazodone].. PubMed.
274. Gagliardi, B., Luscher, V., Monin, Y., Kherad, O., & Coronado, L. (2021). [Sleep disturbances related to nocturnal nuisances in elderly inpatients].. PubMed.
275. Gallagher, B., & Streeter, J. (2014). Patient Outcomes in Mental Disorders. The Wiley Blackwell Encyclopedia of Health, Illness, Behavior, and Society. https://doi.org/10.1002/9781118410868.wbehibs127
276. Gameiro, G. R., Minguini, I. P., & Alves, T. C. T. F. (2014). O papel do estresse e de acontecimentos cotidianos para o desenvolvimento da depressão na terceira idade. Revista de Medicina. https://doi.org/10.11606/issn.1679-9836.v93i1p31-40
277. Ganz, D., & Lindenfeld, L. (2009). Suicidal behavior in adolescents with comorbid depression and alcohol abuse.. PubMed.
278. Gaona, P., & Shirley, C. (2017). Proceso de atención de enfermería a pacientes con ansiedad relacionada a la abstinencia por alcohol según criterio de diagnostico nanda-nic-noc..
279. Garcia, M. O., Garnica, M. M., Marin, S. G., Martínez, C., Martínez, R. G., & Valle, P. B. D. (2017). A child with Pica. A case presentation. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.472
280. García, R. G., Alvarez, M. R., & Arturo, F. (2010). Cefalea por uso excesivo de medicamentos: implicaciones clínicas y terapéuticas Medication over use headache: clinical and therapeutic implications.
281. García‐Palacios, A. (2004). La terapia dialéctico comportamental para el tratamiento del trastorno límite de la personalidad. Informació psicològica/Informació psicològica.
282. Garg, T., & Rawat, V. S. (2023). Trihexyphenidyl Use Disorder and Withdrawal Syndrome. Journal of Psychiatry Spectrum. https://doi.org/10.4103/jopsys.jopsys_12_23
283. Garro, A., Bond, G. R., & Gilbert, D. L. (2007). Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Clinical Toxicology. https://doi.org/10.1080/15563650600981178
284. Garza-Treviño, E. S. (1988). El manejo de urgencia de los cuadros psicóticos agudos. Salud Mental.
285. George, O., Ahmed, S. H., & Gilpin, N. W. (2022). Are we compulsively chasing rainbows?. Neuropsychopharmacology. https://doi.org/10.1038/s41386-022-01419-w
286. Ghaemi, S. N. (2018). Children. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199995486.003.0028
287. Ghaziuddin, N., Gih, D., Barbosa, V., Maixner, D. F., & Ghaziuddin, M. (2010). Onset of Catatonia at Puberty. Journal of Ect. https://doi.org/10.1097/yct.0b013e3181de332e
288. Giannopoulos, I., Jupe, T., & Provi, K. (2024). Sleep architecture disturbance due to the use of benzodiazepines. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2024.1614
289. Giasuddin, N. A., & Hossain, M. J. (2020). Understanding Obsessive Compulsive Disorder and Management Options. Faridpur Medical College Journal. https://doi.org/10.3329/fmcj.v15i1.49009
290. Gilchrist, R. H., & Arnold, L. E. (2008). Long-term Efficacy of ADHD Pharmacotherapy in Children. Psychiatric Annals. https://doi.org/10.3928/00485713-20080101-03
291. Giménez, V. M. M., Mazzei, L., Sanz, R., & Manucha, W. (2022). Cannabinoids as Potential Molecules for Addiction Disorders. Current Protein and Peptide Science. https://doi.org/10.2174/1389203723666220510121031
292. Girolamo, G. D., Dagani, J., Purcell, R., Cocchi, A., & McGorry, P. D. (2011). Age of onset of mental disorders and use of mental health services: needs, opportunities and obstacles. Epidemiology and Psychiatric Sciences. https://doi.org/10.1017/s2045796011000746
293. Glance, J., Gopalan, P., & Ackerman, K. D. (2015). Substance Intoxication and Withdrawal States in the General Medical Setting. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199329311.003.0016
294. Glass, R. M. (1990). Blue mood, blackened lungs. Depression and smoking. JAMA. https://doi.org/10.1001/jama.264.12.1583
295. Glass, R. M. (1990). Blue mood, blackened lungs. Depression and smoking.. PubMed.
296. Goldberg, J. F., Singer, T. M., & Garno, J. L. (2001). Suicidality and substance abuse in affective disorders.. PubMed.
297. Goldfeder, S., Scott, R., & Briggs, J. P. (2023). Forensic Assessments of Alcohol, Cannabis and Methamphetamine Intoxication in Cases of Violent Offending.. PubMed.
298. Gomathy, S. B., Saini, A., Gupta, A., Vishnu, V. Y., Singh, M. B., Bhatia, R., Srivastava, M. P., Radhakrishnan, D. M., Srivastava, A. K., & Rajan, R. (2024). A rare yet treatable case of paroxysmal kinesigenic dyskinesia. Annals of Movement Disorders. https://doi.org/10.4103/aomd.aomd_28_23
299. Gooblar, J., & Beaudreau, S. A. (2018). Anxiety Disorders in Late Life. Oxford Research Encyclopedia of Psychology. https://doi.org/10.1093/acrefore/9780190236557.013.415
300. Gottlieb, S., & Friedman, S. B. (1991). Conduct Disorders in Children and Adolescents. Pediatrics in Review. https://doi.org/10.1542/pir.12.7.218
301. Graddy, R., & Rastegar, D. A. (2020). Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0008
302. Granger, C. E., & Shelly, M. P. (1996). Stressing out, or outing stress?. European Journal of Anaesthesiology. https://doi.org/10.1097/00003643-199611000-00001
303. Grant, J. E., Schreiber, L. R., & Odlaug, B. L. (2013). Phenomenology and Treatment of Behavioural Addictions. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674371305800502
304. Gregg, J. A., Tyson, R. L., & Alvarez, A. W. (2018). Gabapentin abuse: A case presentation on how to manage this growing concern. Journal of Nursing Education and Practice. https://doi.org/10.5430/jnep.v8n11p43
305. Gregorowski, C., Seedat, S., & Jordaan, G. P. (2013). A clinical approach to the assessment and management of co-morbid eating disorders and substance use disorders. BMC Psychiatry. https://doi.org/10.1186/1471-244x-13-289
306. Greydanus, D. E., Calles, J. L., & Patel, D. R. (2008). Anxiety disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544705.007
307. Greydanus, D. E., Calles, J. L., & Patel, D. R. (2008). Substance abuse disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544705.016
308. Grory, S. Y.-M., & Potenza, M. N. (2020). Debates Regarding the Classification, Categorization, and Conceptualization of Problematic Internet Use and Video Gaming. https://doi.org/10.1093/oxfordhb/9780190218058.013.12
309. Grosso, S., Cioni, M., Pucci, L., Morgese, G., & Balestri, P. (1999). Selective mutism, speech delay, dysmorphisms, and deletion of the short arm of chromosome 18: a distinct entity?. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.67.6.830
310. Guerdjikova, A. I., & McElroy, S. L. (2015). Kleptomania. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp147
311. Gunathilake, K. T. B., & Vidanapathirana, M. (2015). Double Murder Following Intoxication with Sedative Drugs. International Journal of Medical Toxicology and Forensic Medicine. https://doi.org/10.22037/ijmtfm.v5i3(summer).8010
312. Gupta, R., Singh, A. P., Mittal, A., & Chaturvedi, S. K. (2024). "FROM BOOST TO BREAKDOWN "PERFORMANCE ENHANCEMENT AND THE DARK SIDE OF MEPHENTERMINE ADDICTION” A CASE SERIES. Global Journal For Research Analysis. https://doi.org/10.36106/gjra/0506138
313. Guszkowska, M. (2013). [Exercise dependence--symptoms and mechanisms].. PubMed.
314. Gómez, C. C. R., Serrano‐Dueñas, M., Bernal, O., Araoz, N., Farret, M. S., Aldinio, V., Montilla, V., & Micheli, F. (2017). A Multicenter Comparative Study of Impulse Control Disorder in Latin American Patients With Parkinson Disease. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0000000000000202
315. Gómez, M. V. (2005). Cefalea crónica diaria: II. Tratamiento. Revista de Neurología. https://doi.org/10.33588/rn.4003.2004387
316. Güleç, H., Babayiğit, M., Kurtay, A., Şahap, M., Ulus, F., Tutal, Z. B., & Horasanlı, E. (2014). Seizure due to multiple drugs intoxication: a case report. Brazilian Journal of Anesthesiology (English Edition). https://doi.org/10.1016/j.bjane.2014.02.013
317. Gündoğmuş, İ., Karagöz, A., & Algül, A. (2018). First-episode psychosis induced by pregabalin withdrawal: a case report. Psychiatry and Clinical Psychopharmacology. https://doi.org/10.1080/24750573.2018.1452523
318. Hachey, L. M., Gregg, J. A., Pavlik-Maus, T. L., & Jones, J. S. (2017). Health implications and management of women with opioid use disorder. Journal of Nursing Education and Practice. https://doi.org/10.5430/jnep.v7n8p57
319. Hall, S. W. (2011). Idiopathic Environmental Intolerances. SpringerReference. https://doi.org/10.1007/springerreference_44303
320. Hall, S., & Ibrahim, S. (2023). 0998 Duloxetine as a Possible Effective Treatment of Klein-Levin Syndrome Case Report. SLEEP. https://doi.org/10.1093/sleep/zsad077.0998
321. Hall, W., Talbert, R. L., & Ereshefsky, L. (1990). Cocaine Abuse and Its Treatment. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/j.1875-9114.1990.tb02550.x
322. Hamed, S. A. (2017). The auditory and vestibular toxicities induced by antiepileptic drugs. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2017.1372420
323. Harding, S. (2005). Continuing Professional Development Managing delirium in older people.
324. Harry, P. (1997). [Acute poisoning by new psychotropic drugs].. PubMed.
325. Harten, P. N. V. (2002). [Drug-induced akathisia].. PubMed.
326. Hartston, H. (2012). The Case for Compulsive Shopping as an Addiction. Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.2012.660110
327. Hawes, D. J., & Scalise, P. (2005). Childhood depression: early risk and resilience and introducing solids to infants. https://doi.org/10.4225/50/5552facc15227
328. Hayes, A., & Lingford‐Hughes, A. (2023). Drug Use, Addiction, Tolerance, Withdrawal and Relapse. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623137.058
329. Heidari, A. (2023). Bibliometric Analysis of Worldwide Scientific Books on Effects of COVID-19 Extensive Disease on Mental Fitness. New Medical Innovations and Research. https://doi.org/10.31579/2767-7370/081
330. Heilig, M. (2023). Stress‐related neuropeptide systems as targets for treatment of alcohol addiction: A clinical perspective. Journal of Internal Medicine. https://doi.org/10.1111/joim.13636
331. Henkin, R. I., & Abdelmeguid, M. (2020). Smell Loss and Onset of Phantosmia are Critical Aspects of Head Injury Cognition. The FASEB Journal. https://doi.org/10.1096/fasebj.2020.34.s1.02320
332. Hernández, G., García, L. H., Baez, I. C., Rodrigo, A. M., Torres, C. D., Gómez-Juanes, R., & Pérez, P. G. (2023). Antiandrogenic treatment of obsessive compulsive neurosis: A case review. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1961
333. Hesapçıoğlu, S. T., Bilgier, S., & Kandil, S. (2013). ERGENLİKTE TEKRARLAYICI SUÇ İŞLEME, ALPRAZOLAM VE DİĞER MADDE BAĞIMLILIKLARI BİRLİKTELİĞİ. DergiPark (Istanbul University). https://doi.org/10.17343/sdutfd.30699
334. Hillman, D. R., Carlucci, M., Charchaflieh, J., Cloward, T. V., Gali, B., Gay, P. C., Lyons, M. M., McNeill, M. M., Singh, M., Yılmaz, M., & Auckley, D. (2023). Society of Anesthesia and Sleep Medicine Position Paper on Patient Sleep During Hospitalization. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000006395
335. Hirschfeld, R. M. A. (1996). Long-term drug treatment of unipolar depression. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199612000-00001
336. Hirschfeld, R. M. A., Calabrese, J. R., Frye, M. A., Lavori, P. W., Sachs, G., Thase, M. E., & Wagner, K. D. (2007). Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening.. PubMed.
337. Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2024). Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01880-2
338. Hoehn‐Saric, R., Lipsey, J. R., & McLeod, D. R. (1990). Apathy and Indifference in Patients on Fluvoxamine. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199010000-00007
339. Hoell, I., & Havemann‐Reinecke, U. (2011). [Pregnant opioid addicted patients and additional drug intake. Part I. Toxic effects and therapeutic consequences].. PubMed.
340. Hohmann, N., Mikus, G., & Czock, D. (2014). Effects and Risks Associated with Novel Psychoactive Substances. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2014.0139
341. Hong, I. S., & Bishop, J. R. (2014). Geriatric Patients: Choose Wisely: Age-Related Physiologic Changes, Risk of Adverse Effects Guide Your Prescribing. Current psychiatry.
342. Hosztafi, S. (2011). [Heroin addiction].. PubMed.
343. Howard, M. O., Garland, E. L., Sharp, C. W., & Beauvais, F. (2015). Substance Abuse: Inhalant‐Related Disorders. Psychiatry. https://doi.org/10.1002/9781118753378.ch77
344. Howland, R. H. (2014). Gabapentin for Substance Use Disorders: Is it Safe and Appropriate?. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20131217-01
345. Hsieh, M. T., Peng, W., Wu, C., Ng, K., Cheng, C. Y., & Xu, H. (2010). None. Planta Medica. https://doi.org/10.1055/s-002-20741
346. Huang, K., & Tsai, S. (2012). The importance of measuring impulsiveness in patients with addiction problems. Journal of the Chinese Medical Association. https://doi.org/10.1016/j.jcma.2012.10.003
347. Hubbard, J. P., Everett, A., & Khan, M. A. (1996). Alcohol and Drug Abuse in Patients with Physical Disabilities. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.3109/00952999609001655
348. Hyytiä, P. (2015). [The effect of abused drugs on the developing brain during childhood and adolescence].. PubMed.
349. Håkansson, A., & Johansson, B. (2015). Atypical course in severe catatonic schizophrenia in a cannabis-dependent male adolescent: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-015-0678-5
350. Iftikhar, M. (2020). Persistent Depressive Disorder More Than We See and Treat. SSRN Electronic Journal.
351. Isac, A. (2018). Therapeutic Recommendations for Treating Depression in Children and Adolescents. Psihiatru ro. https://doi.org/10.26416/psih.53.2.2018.1784
352. Isbell, H., & Fraser, H. F. (1950). ADDICTION TO ANALGESICS AND BARBITURATES. Pharmacological Reviews.
353. Isbell, H., & Fraser, H. F. (1950). ADDICTION TO ANALGESICS AND BARBITURATES. Pharmacological Reviews. https://doi.org/10.1016/s0031-6997(25)07083-8
354. Ivlieva, N. Y. (2011). [Neurobiology of addictive behavior].. PubMed.
355. İnce, C., Karakuş, M., Karadeniz, S., & Kandil, S. (2014). Atomoksetin Kullanımı Sırasında Gelişen Bir Obsesif Kompulsif Bozukluk Olgusu. Turkish Journal of Pediatric Disease.
356. Jablensky, A. (2012). Course and outcome of schizophrenia and their prediction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0078
357. Jacob, M. S., Carlen, P. L., Marshman, J. A., & Sellers, E. M. (1981). Phencyclidine Ingestion: Drug Abuse and Psychosis. International Journal of the Addictions. https://doi.org/10.3109/10826088109038866
358. Jacobs, W., Thiesbrummel, A. W., & Zylic, Z. (1998). [Treatment of restlessness in dying patients: more than just sedation].. PubMed.
359. Jahan, A. R., & Burgess, D. M. (2021). Substance Use Disorder. StatPearls.
360. Jain, S., Goel, S., & Kapila, S. (2015). Clinical Evaluation Of Psychiatric Emergencies.
361. James, N. M., & Lewis, P. J. E. (1973). Haloperidol and Chlorpromazine: A Double-Blind Cross-Over Trial and Clinical Study in Children and Adolescents. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.3109/00048677309161478
362. Jansen, K. (1990). Ketamine–Can Chronic Use Impair Memory. International Journal of the Addictions. https://doi.org/10.3109/10826089009056204
363. Jefferson, R. D., Bateman, D. N., Thomas, S. H., Thompson, J. P., & Vale, J. A. (2014). Drugs of abuse. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199594740.003.0008
364. Jeon, H. J. (2023). Clinical presentation, diagnosis, and treatment of sleep disorders in adolescents. Journal of Korean Medical Association. https://doi.org/10.5124/jkma.2023.66.4.258
365. Jevtovic, J., Jovanović, J., Grujicic, M. V. –., & Vujcic, J. (2021). OCCUPATIONAL STRESS IN COMPUTER OPERATORS. Knowledge International Journal.
366. Jiménez, C., & Belén, M. (2019). Terapia de aceptación y compromiso grupal aplicada a pacientes adictos a los opioides con el manejo de los síntomas de abstinencia junto con la terapia farmacológica para evitar recaídas a futuro.
367. Jing-y, L. (2013). Attentional defects induced by chronic drug abuse. Journal of Capital Medical University.
368. Johnson, J., & Buisman‐Pijlman, F. (2016). Adversity impacting on oxytocin and behaviour: timing matters. Behavioural Pharmacology. https://doi.org/10.1097/fbp.0000000000000269
369. Jones, E. M., Knutson, D., & Haines, D. (2003). Common problems in patients recovering from chemical dependency.. PubMed.
370. Jonge, M. E. A.-D., Portier, C., & Franssen, E. J. F. (2007). [Automutilation after consumption of hallucinogenic mushrooms].. PubMed.
371. Jovanović, D., Todorović, Randjelović, S., & Kuśić, R. (1989). Acute poisoning by herbicide compounds.
372. Judd, L. L., Schettler, P. J., Brown, E. S., Wolkowitz, O. M., Sternberg, E. M., Bender, B. G., Bulloch, K., Cidlowski, J. A., Kloet, E. R. D., Fardet, L., Joëls, M., Leung, D. Y., McEwen, B. S., Roozendaal, B., Rossum, E. F. C. V., Ahn, J., Brown, D. W., Plitt, A., & Singh, G. (2014). Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2014.13091264
373. Kalivas, P. W. (2003). Development and Expression of Behavioral Sensitization. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_9
374. Kalivas, P. W., Toda, S., Bowers, M. S., Baker, D. L., & Ghasemzadeh, M. B. (2003). The Temporal Sequence of Changes in Gene Expression by Drugs of Abuse. Humana Press eBooks. https://doi.org/10.1385/1-59259-358-5:03
375. Kallan, F. M., Siya, A., Kolenchery, J. J., D'silva, V. R., Nagdive, A., & Sethi, S. (2021). Seizures Presenting as ADHD: A Case Report. Journal of Pharmaceutical Research International. https://doi.org/10.9734/jpri/2021/v33i60b35017
376. Kalsi, S. S., Wood, D. M., & Dargan, P. I. (2011). The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerging Health Threats Journal. https://doi.org/10.3402/ehtj.v4i0.7107
377. Kane, J. M., & Mayerhoff, D. (1989). Do Negative Symptoms Respond to Pharmacological Treatment?. The British Journal of Psychiatry. https://doi.org/10.1192/s0007125000291630
378. Kapała, W., Kapała, A., & Wojtyła-Buciora, P. (2023). Psychoactive Substances and Selected Health Problems Related to Their Use. https://doi.org/10.2478/bgbl-2023-0036
379. Karila, L., Lowenstein, W., Coscas, S., Benyamina, A., & Reynaud, M. (2009). [Complications of cocaine addiction].. PubMed.
380. Karila, L., Roux, P., Rolland, B., Benyamina, A., Reynaud, M., Aubin, H., & Lançon, C. (2014). Acute and Long-Term Effects of Cannabis Use: A Review. Current Pharmaceutical Design. https://doi.org/10.2174/13816128113199990620
381. Kavanaugh, B. C., Dupont-Frechette, J. A., Jerskey, B. A., & Holler, K. (2016). Neurocognitive deficits in children and adolescents following maltreatment: Neurodevelopmental consequences and neuropsychological implications of traumatic stress. Applied Neuropsychology Child. https://doi.org/10.1080/21622965.2015.1079712
382. Kaware, M. A. S., Dudhe, M. P. V., Chavhan, M. N. R., Naveria, M. A., & Rajeshwari, K. R. (2024). An Retrospective Study of Commonly Prescribed Antiepileptic Drugs and it’s Interaction with Other Drugs which are Already in use Respect to Other Disease. International Journal of Advanced Research in Science Communication and Technology. https://doi.org/10.48175/ijarsct-18578
383. Keary, C. J., Nejad, S. H., Rasimas, J. J., & Stern, T. A. (2013). Intoxications Associated With Agitation, Tachycardia, Hypertension, and Fever: Differential Diagnosis, Evaluation, and Management. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.12f01459
384. Keller, M. B., & Berndt, E. R. (2002). Depression treatment: a lifelong commitment?. PubMed.
385. Kendall, T. J., Taylor, E., Perez, A., & Taylor, C. D. J. (2008). Diagnosis and management of attention-deficit/hyperactivity disorder in children, young people, and adults: summary of NICE guidance. BMJ. https://doi.org/10.1136/bmj.a1239
386. Kerfoot, M. (2005). Partnerships between health and local authorities. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198508441.003.0008
387. Khantzian, E. J. (1990). Self-regulation and self-medication factors in alcoholism and the addictions. Similarities and differences.. PubMed.
388. Killick, L., Carlyle, W., & Ancill, R. (1991). ECT: An Effective Treatment in the Screaming Demented Patient. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.1991.tb03610.x
389. Kim, E. K. E., & Beckmann, D. (2021). An adolescent with binge drinking. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0027
390. Kintz, P., Blanchot, A., Farrugia, A., & Goullé, J. (2025). [Toxicological aspects of chemical submission].. PubMed.
391. Kintz, P., Villain, M., & Cirimele, V. (2008). Chemical Abuse in the Elderly: Evidence From Hair Analysis. Therapeutic Drug Monitoring. https://doi.org/10.1097/ftd.0b013e31816bac44
392. Kintz, P., Villain, M., Cirimele, V., Goullé, J., & Ludes, B. (2002). [Crime under the influence of psychoactive drugs: the problem of the duration of detection].. PubMed.
393. Klaassen, T. (2021). Novel strategies to address disrupted sensing and signalling of satiety. https://doi.org/10.26481/dis.20210903tk
394. Klega, A. E., & Keehbauch, J. (2018). Stimulant and Designer Drug Use: Primary Care Management.. PubMed.
395. Klein, S. (2015). Autistic phenomena in neurotic patients 1. Routledge eBooks. https://doi.org/10.4324/9781315743882-10
396. Knight, E., & McIntyre, A. (2012). Pharmacy medications and driving: delivering key information to ageing drivers.
397. Koenigsberg, H. W. (1997). Integrating psychotherapy and pharmacotherapy in the treatment of borderline personality disorder. In Session Psychotherapy in Practice. https://doi.org/10.1002/(sici)1520-6572(199722)3:2<39::aid-sess4>3.0.co;2-3
398. Kolla, B., & Hocker, S. E. (2021). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0045
399. Koller, W. C., Weiner, W. J., Perlik, S., Nausieda, P. A., Goetz, C. G., & Klawans, H. L. (1981). Complications of chronic levodopa therapy. Neurology. https://doi.org/10.1212/wnl.31.4.473
400. Koller, W. C., Weiner, W. J., Perlik, S., Nausieda, P. A., Goetz, C. G., & Klawans, H. L. (1981). Complications of chronic levodopa therapy. Neurology. https://doi.org/10.1212/wnl.31.4_part_2.473
401. Kondziella, D., Danielsen, E. R., & Arlien‐Soeborg, P. (2006). Fatal encephalopathy after an isolated overdose of cocaine. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2006.088955
402. Koo, S. K. (2018). Depression Status in Korea. Osong Public Health and Research Perspectives. https://doi.org/10.24171/j.phrp.2018.9.4.01
403. Koob, G. F. (2013). Neurocircuitry of Addiction: A brain reward deficit, stress surfeit and executive function disorder. Suchttherapie. https://doi.org/10.1055/s-0033-1351398
404. Koob, G. F. (2020). Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development. Pharmacological Reviews. https://doi.org/10.1124/pharmrev.120.000083
405. Koob, G. F., Kandel, D. B., & Volkow, N. D. (2008). Pathophysiology of Addiction. Psychiatry. https://doi.org/10.1002/9780470515167.ch22
406. Kosten, T. R. (1991). Client issues in drug abuse treatment: addressing multiple drug abuse.. PubMed.
407. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
408. Koçak, Ö., & Koçak, S. (2023). Underrated Diagnosis: Prenatal Depression. Kafkas Journal of Medical Sciences. https://doi.org/10.5505/kjms.2023.21033
409. Kramer, L. D., Locke, G. E., Ogunyemi, A. O., & Nelson, L. (1990). Cocaine-Related Seizures in Adults. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.3109/00952999009001592
410. Kreek, M. J. (2011). Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2011.06152.x
411. Kresina, T. F., Normand, J., Khalsa, J., Mitty, J. A., Flanigan, T., & Francis, H. (2004). Addressing the Need for Treatment Paradigms for Drug-Abusing Patients with Multiple Morbidities. Clinical Infectious Diseases. https://doi.org/10.1086/421403
412. Kruger, A. (1996). Chronic Psychiatric Patients' Use of Caffeine: Pharmacological Effects and Mechanisms. Psychological Reports. https://doi.org/10.2466/pr0.1996.78.3.915
413. Krüger, R. T. (2024). Addiction Disorders. Psychodrama in Counselling, Coaching and Education. https://doi.org/10.1007/978-981-99-7508-2_10
414. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część I. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.27
415. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część II. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.33
416. Kumari, D., & Kumar, P. (2023). Psychosocial Functioning of Females with Chronic Anxiety Disorder. Journal of Psychosocial Well-being. https://doi.org/10.55242/jpsw.2023.4107
417. Kumari, V. (2021). New insights on affective morbidity and childhood maltreatment. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.121
418. Kurz, A. (1996). [Prognostic aspects of panic disorder].. PubMed.
419. Kutluay, E., & Edwards, J. (2015). Epilepsy and Alcohol and Substance Abuse. https://doi.org/10.1002/9781118951026.ch23
420. Kyle, P. B., Iverson, R. B., Gajagowni, R. G., & Spencer, L. (2011). Illicit bath salts: not for bathing.. PubMed.
421. Laird, L. K., & Saklad, J. J. (1990). Attention-Deficit Hyperactivity Disorder. Journal of Pharmacy Practice. https://doi.org/10.1177/089719009000300406
422. Landry, M. J., Smith, D. E., McDuff, D., & Baughman, O. L. (1992). Benzodiazepine dependence and withdrawal: identification and medical management.. PubMed.
423. Langguth, B., Bär, R., Wodarz, N., Wittmann, M., & Laufkötter, R. (2011). Paradoxical Reaction in ADHD. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2011.0541a
424. Lansky, M. R., & Simenstad, E. A. (1986). Narcissistic vulnerability in a group for psychiatrically hospitalized fathers. Group. https://doi.org/10.1007/bf01469396
425. Latt, N., Conigrave, K. M., Saunders, J. B., Marshall, E. J., & Nutt, D. (2009). Chapter 10 Other drugs. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199539338.003.0010
426. Lavin, M. (2010). Voyeurism. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy1030
427. Law, F., & Nutt, D. (2012). Drugs used in the treatment of the addictions. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0158
428. Lee, H., Kim, J., Lee, H.-S., Jo, Y.-H., Ko, J.-A., In, S., & Lee, J.-B. (2023). MS Fragmentation of ALD-52 with GC-MS and LC-QTOF. Korean Journal of Forensic Science. https://doi.org/10.53051/ksfs.2023.24.1.2
429. Lee, M. (2010). Medication, Drug and Alcohol Use and Abuse Amongst Middle-Aged Adults.
430. Lee, S.-H., Song, D., Kim, B.-N., Joung, Y., Ha, E. H., Cheon, K., Shin, Y., Yoo, H. J., & Shin, D. (2009). Variability of Response Time as a Predictor of Methylphenidate Treatment Response in Korean Children with Attention Deficit Hyperactivity Disorder. Yonsei Medical Journal. https://doi.org/10.3349/ymj.2009.50.5.650
431. Lee, V. (2021). Mental Health Impacts during COVID-19. Journal of Anxiety & Depression. https://doi.org/10.46527/2582-3264.136
432. Lehman, T. J. A. (2004). The Child Who Hurts All Over. https://doi.org/10.1093/oso/9780195157284.003.0004
433. Lejoyeux, M., & Adès, J. (1993). [Psychiatric emergencies in acute alcoholic intoxication].. PubMed.
434. Lheureux, P., & Penaloza, A. (2004). [Ototoxicity-related dysequilibrium].. PubMed.
435. Li, Z., Goh, S. N., Teo, Y. W., & How, C. H. (2023). Management of intimate partner abuse. Singapore Medical Journal. https://doi.org/10.4103/singaporemedj.smj-2021-452
436. Ligier, F., & Kabuth, B. (2016). Between Neurology and Psychiatry, a Difficult Preliminary Diagnosis of Kleine-levin Syndrome: Case-report of a Young Girl. Journal of Child and Adolescent Behaviour. https://doi.org/10.4172/2375-4494.1000274
437. Linzer, S., Chesir, A., Ginsburg, T., & Varas, O. (2017). Stressful Life Events. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190260859.003.0005
438. Lipsey, J. R. (2008). Electroconvulsive Therapy. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195309430.003.0029
439. Liu, G., Slater, N., & Perkins, A. (2017). Epilepsy: Treatment Options.. PubMed.
440. Llcms, L. C., Martins, P. R. C., Loures, É. N., Vitalino, A. R., Lotufo, C. C., & Onady, S. Y. (2017). ATAQUE ISQUÊMICO TRANSITÓRIO E ESTADO DE MAL EPILÉPTICO COMO MANIFESTAÇÕES DE INTOXICAÇÃO AGUDA E ABSTINÊNCIA POR CRACK E COCAÍNA.
441. Lockhart, P. J. (2001). Fetal alcohol spectrum disorders for mental health professionals - a brief review. Current Opinion in Psychiatry. https://doi.org/10.1097/00001504-200109000-00007
442. Logan, B. K., & Couper, F. J. (2003). 3,4-Methylenedioxymethamphetamine - Effects on Human Performance and Behavior.. PubMed.
443. Logožar, M. (2020). Depresija kao rizični čimbenik za školski uspjeh kod adolescenata.
444. Loitman, J. E., & Deshields, T. L. (2010). Psychiatric Palliative Care Issues. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-590-3_4
445. Lozano, R. P., García, Y. Á., Tafalla, D. B., & Albaladejo, M. F. (2007). Cafeína: un nutriente, un fármaco, o una droga de abuso. Adicciones. https://doi.org/10.20882/adicciones.303
446. Lyvers, M. (1998). Drug addiction as a physical disease: The role of physical dependence and other chronic drug-induced neurophysiological changes in compulsive drug self-administration.. Experimental and Clinical Psychopharmacology. https://doi.org/10.1037//1064-1297.6.1.107
447. Lyvers, M. (1998). Drug addiction as a physical disease: The role of physical dependence and other chronic drug-induced neurophysiological changes in compulsive drug self-administration.. Experimental and Clinical Psychopharmacology. https://doi.org/10.1037/1064-1297.6.1.107
448. López‐Caneda, E., Holguı́n, S. R., Cadaveira, F., Corral, M., & Doallo, S. (2013). Impact of Alcohol Use on Inhibitory Control (and Vice Versa) During Adolescence and Young Adulthood: A Review. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agt168
449. Macho, L. P., & Andrés, S. B. (2010). Trastornos digestivos en la enfermedad de Parkinson: atonía gástrica, malabsorción y estreñimiento. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009740
450. Madan, A., Frueh, B. C., Fowler, J. C., Stomberg, S., Bradshaw, M. R., Kelly, K. R., Weinstein, B., Luttrell, M., Danner, S. G., & Beidel, D. C. (2020). “Operator syndrome”: A unique constellation of medical and behavioral health-care needs of military special operation forces. The International Journal of Psychiatry in Medicine. https://doi.org/10.1177/0091217420906659
451. Madrid, P. A., Grant, R., Reilly, M. J., & Redlener, N. B. (2006). Challenges in Meeting Immediate Emotional Needs: Short-term Impact of a Major Disaster on Children's Mental Health: Building Resiliency in the Aftermath of Hurricane Katrina. PEDIATRICS. https://doi.org/10.1542/peds.2006-0099u
452. Maeda, M., Nagasawa, H., Yorizumi, K., Sayama, S., & Ogino, H. (1991). Compulsive Manipulation of Tools and Its Clinical Symptomatology.. Shitsugoshō kenkyū/Shitsugoshou kenkyuu. https://doi.org/10.2496/apr.11.187
453. Magyar, M., Hajnal, B., Gyüre, T., & Ertsey, C. (2015). Fájdalomcsillapító-túlhasználathoz társuló fejfájás. Orvosi Hetilap. https://doi.org/10.1556/650.2015.30209
454. Mahato, T. K., Ojha, S. K., Singh, V., & Parihar, S. P. S. (2021). Addiction withdrawal syndrome: Needs medications, education, counselling &amp; support. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2021.12.2.0573
455. Maierà, E. (2010). Old age depression and its treatment.. PubMed.
456. Majewska, M. (1996). Cocaine Addiction as a Neurological Disorder: Implications for Treatment. PsycEXTRA Dataset. https://doi.org/10.1037/e495672006-002
457. Mallick, A., & Pan, D. (2015). Psychosocial Care in Old Age-gateway to Quality Mental Health. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)31113-5
458. Manber, R., Ong, J. C., & Carlyle, E. (2008). Diagnostic Tools for Insomnia. CRC Press eBooks. https://doi.org/10.3109/9781420019926-6
459. Manschreck, T. C. (1996). Delusional disorder: the recognition and management of paranoia.. PubMed.
460. Marazziti, D., Avella, M. T., Ivaldi, T., Palermo, S., Massa, L., Vecchia, A. D., Basile, L., & Mucci, F. (2021). Neuroenhancement: State of the Art and Future Perspectives.. PubMed. https://doi.org/10.36131/cnfioritieditore20210303
461. Marchesi, C., Tonna, M., & Maggini, C. (2008). Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse. The World Journal of Biological Psychiatry. https://doi.org/10.1080/15622970701459828
462. Maremmani, I., Pacini, M., & Maremmani, A. G. I. (2023). Chronic Psychosis in Dual Disorder Heroin Use Disorder Patients. https://doi.org/10.1007/978-3-031-30093-6_4
463. Maremmani, I., Pacini, M., Lamanna, F., Pani, P., Perugi, G., Deltito, J., Salloum, I. M., & Akiskal, H. S. (2010). Mood Stabilizers in the Treatment of Substance Use Disorders. CNS Spectrums. https://doi.org/10.1017/s1092852900027346
464. Markham, R. A., & Watts, S. (2005). Etiology of Depression in Children.. Journal of instructional psychology.
465. Markland, A. D., Busby‐Whitehead, J., & Whitehead, W. E. (2022). Fecal Incontinence. Cambridge University Press eBooks. https://doi.org/10.1017/9781108942751.029
466. Marković, H., Nikolac, N., Tripković, M., Haluga-Golubović, I., & Čustović, Z. (2012). Connection between Addictive Behavior and Investing on the Stock Market in Croatia.
467. Marshall, L. L., & Bailey, W. (2008). Urinary Incontinence Management in Geriatric Patients. The Consultant Pharmacist. https://doi.org/10.4140/tcp.n.2008.681
468. Mary, L. A. (2013). A Study on Depression, Anxiety and Quality of Life ofChronic Renal Failure Patients on Maintenance Hemodialysis..
469. Marzal, G. P., Rigual, F. C., Soto, B. B., & Olivares, J. Q. (2015). Psicoestimulantes en la infancia: ¿Medicalización o mejoramiento?.
470. Masdrakis, V. G., Turic, D., & Baldwin, D. S. (2013). Pharmacological Treatment of Social Anxiety Disorder. Modern trends in psychiatry. https://doi.org/10.1159/000351960
471. Masi, G., Millepiedi, S., & Mucci, M. (2002). Efficacy of newer antidepressants for childhood anxiety disorders. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.2.4.523
472. Mattison, A., & Cherner, M. (2005). Club drugs and HIV transmission. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198526100.003.0067
473. Mbizvo, G. K., Dixon, P., Hutton, J. L., & Marson, A. G. (2013). The adverse effects profile of levetiracetam in epilepsy: a more detailed look. International Journal of Neuroscience. https://doi.org/10.3109/00207454.2013.866951
474. Mc, H., Schmer, D., Waingortin, D., Cervone, N., & Ma, F. (1976). [Study and treatment of the drug addict and his family].. PubMed.
475. Mc, M.-S. (1993). [Post-traumatic stress syndrome in children].. PubMed.
476. McArdle, P., & Angom, B. (2012). Adolescent substance misuse: an update on behaviours and treatments. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.bp.106.003327
477. McCrae, C. S., Ross, A., Stripling, A. M., & Dautovich, N. D. (2007). Eszopiclone for late-life insomnia.. PubMed.
478. McFadden, K. M. (2010). Cross-Addiction: From Morbid Obesity to Substance Abuse. Bariatric Nursing and Surgical Patient Care. https://doi.org/10.1089/bar.2010.9922
479. McGorry, P. D., & Yung, A. R. (2020). Transition to adulthood. Routledge eBooks. https://doi.org/10.4324/9780429285806-2
480. McGorry, P. D., Purcell, R., Goldstone, S., & Amminger, G. P. (2011). Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of care. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0b013e3283477a09
481. McLeod, T. C. V., & Register‐Mihalik, J. K. (2011). Clinical Outcomes Assessment for the Management of Sport-Related Concussion. Journal of Sport Rehabilitation. https://doi.org/10.1123/jsr.20.1.46
482. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
483. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
484. Meehan, T. J., Bryant, S. M., & Aks, S. E. (2010). Drugs of Abuse: The Highs and Lows of Altered Mental States in the Emergency.
485. Meena, D., Chand, S., & Kumar, D. (2019). A Review Article on Selective Serotonin Reuptake Inhibitors (SSRIS). Asian Journal of Pharmaceutical Research and Development. https://doi.org/10.22270/ajprd.v7i6.592
486. Mehdiratta, N., Kalita, S., & Hirsch, A. R. (2023). Generalized Restless Body Syndrome: A case of opioid withdrawal- induced restlessness extending beyond the legs. https://doi.org/10.14293/p2199-8442.1.sop-.ptttfx.v1
487. Mellero, D. (2007). Ansiedade em situações de convívio social em idosos.
488. Menezes, M. C. D. C., Gonçalves, L. G. V., Chaves, S. C. D. S., Jaime, T. F. M., Oliveira, I. C. Z., Sobrinho, K. D. L., Oliveira, L. L. D., Araújo, J. V. L. D., Gurian, F. G., Soares, I. L. T., Nero, L. D., Pereira, P. H. D. O., Moraes, F. D. C., & Teixeira, G. P. (2023). MAIN CAUSES OF INTENTIONAL ACCIDENTS IN PEDIATRICS AND CLINICAL MANIFESTATIONS - LITERATURE REVIEW. International Journal of Health Science. https://doi.org/10.22533/at.ed.1593712308095
489. Menzel, J. E., & Thompson, J. K. (2010). Food Addiction. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0365
490. Meza-Ruiz, W., & Zúñiga-Escobar, G. (2023). Hematoma cerebral intraparenquimatoso e intraventricular por cocaína: reporte de un caso. Revista chilena de neuro-psiquiatría. https://doi.org/10.4067/s0717-92272023000100064
491. Michie, S. (2002). CAUSES AND MANAGEMENT OF STRESS AT WORK. Occupational and Environmental Medicine. https://doi.org/10.1136/oem.59.1.67
492. Miles, N., Moyko, A., & Alao, A. K. (2013). 2202 – Stop and don’t smell the shoe polish. The use of inhalants among adolescents. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77075-5
493. Miličević, V. (2014). Utjecaj bolesti ovisnosti na usnu šupljinu.
494. Miller, A. (2018). Ritual abuse and mind control: the definition evolves. Routledge eBooks. https://doi.org/10.4324/9780429475467-2
495. Miller, D. D. (2007). Sedation with Antipsychotics: Manage, Don't Accept Adverse 'Calming' Effect. Current psychiatry.
496. Miyasato, K. (2013). [Psychiatric and psychological features of nicotine dependence].. PubMed.
497. Mkize, D. L. (2003). Evidence-based interventions for dementia in general practice : main topic. CME: Your SA Journal of CPD.
498. Mlakar, P., & Stare, J. (2014). Some Characteristics of Employees as Risk Factors for Presenteeism. Central European Public Administration Review. https://doi.org/10.17573/ipar.2013.2.a02
499. Modigh, K., Berggren, U., & Sehlin, S. (1998). [High risk for children with DAMP/ADHD to become addicts later in life].. PubMed.
500. Moguel, B., Armenta, M., & Hernández, V. (1993). [Clinico-pathologic correlation of dementia produced by thinner and cocaine].. PubMed.
501. Mohammadi, M. R., & Akhondzadeh, S. (2007). Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.7.2.195
502. Mohanty, I., Arunvikram, K., Sardar, K. K., Palai, S., Sahoo, G., & Patra, R. C. (2014). Adverse drug reaction and toxicity caused by commonly used antimicrobials in canine practice. Veterinary World. https://doi.org/10.14202/vetworld.2014.299-305
503. Monotti, R. (1993). [Drug emergencies].. PubMed.
504. Montoya, A., & Alejandra, M. (2020). Estrés laboral y sus consecuencias en la salud que afectan el rendimiento.
505. Moorthi, K., Pertin, S., & Radhika, P. (2023). Homoeopathy for obsessive-compulsive disorder: A case report. Indian Journal of Research in Homoeopathy. https://doi.org/10.53945/2320-7094.1117
506. Morissette, S. B., Tull, M. T., Gulliver, S. B., Kamholz, B. W., & Zimering, R. T. (2007). Anxiety, anxiety disorders, tobacco use, and nicotine: A critical review of interrelationships.. Psychological Bulletin. https://doi.org/10.1037/0033-2909.133.2.245
507. Moro‐de‐Casillas, M. L., & Riley, D. E. (2012). Insomnia in Parkinson’s Disease. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-429-6_17
508. Morrigan, C. (2017). Failure to Comply: Madness and/as Testimony. Canadian Journal of Disability Studies. https://doi.org/10.15353/cjds.v6i3.366
509. Morton, W. A. (1999). Cocaine and Psychiatric Symptoms. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.v01n0403
510. Mude, G., Pise, S., Makade, K., Fating, R., & Wakodkar, S. (2021). Termiticidal Activity of Ethanolic and n- Hexane Leaf Extraction of Calotropis procera, Cannabis indica and Mentha longifolia Against a Higher Termite Microtomes obesi. Journal of Developing Drugs. https://doi.org/10.35248/2329-6631.21.10.206
511. Muliyala, K. P., Lima, C. A. D. M., & Chong, D. (2024). S9: Addictions in Later Life an Emerging Crisis. International Psychogeriatrics. https://doi.org/10.1017/s104161022400111x
512. Mullen, S. (2018). Major depressive disorder in children and adolescents. Mental Health Clinician. https://doi.org/10.9740/mhc.2018.11.275
513. Muncie, H. L., Yasinian, Y., & Oge, L. K. (2013). Outpatient management of alcohol withdrawal syndrome.. PubMed.
514. Munir, S., & Takov, V. (2021). Generalized Anxiety Disorder. StatPearls.
515. Munir, S., Takov, V., & Coletti, V. A. (2021). Generalized Anxiety Disorder (Nursing).
516. Musálek, M. (2011). Pathologisches Spielen: Impulskontrollstörung oder Sucht?. Suchttherapie. https://doi.org/10.1055/s-0031-1284655
517. Müller, C. P. (2013). Episodic Memories and Their Relevance for Psychoactive Drug Use and Addiction. Frontiers in Behavioral Neuroscience. https://doi.org/10.3389/fnbeh.2013.00034
518. Na, I., & Volel, B. A. (2002). [Clinical aspects of "folie du doute"].. PubMed.
519. Naidoo, S. (2015). Managing stress in the dental environment.
520. Nakamura, A., & Tanaka, K. (2023). A boy with dissociative symptoms who benefited from biopsychosocial assessment. Pediatrics International. https://doi.org/10.1111/ped.15502
521. Nakayama, H., Mihara, S., Sakuma, H., Kitamura, D., & Higuchi, S. (2014). SY08-3 * CO-MORBIDITY OF INTERNET ADDICTION. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agu052.39
522. Nasrallah, H. A. (2014). Clozapine Is a Vastly Underutilized, Unique Agent with Multiple Applications. Current psychiatry.
523. Nayak, R. D. (2015). Internet Addiction a Comparative Study between Undergraduate Students of India and Malaysia. International Journal of Indian Psychology. https://doi.org/10.25215/0204.088
524. Nazlı, Ş. B., & Sevindik, M. (2020). Use of methylphenidate in co-existing major depression and loss of libido and erectile dysfunction: a case report. Anatolian Journal of Psychiatry. https://doi.org/10.5455/apd.112405
525. Neavins, T. M., Easton, C. J., Brotchie, J., & Carroll, K. M. (2008). Empirically validated psychological therapies for drug dependence. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544392.020
526. Nehretskii, S. (2023). Interdisciplinary Forensic and Pharmaceutical, Organizational and Legal, Clinical and Pharmacological Study of Abuse of Psychoactive Substances. SSP Modern Pharmacy and Medicine. https://doi.org/10.53933/sspmpm.v3i1.85
527. Neufeld, K. J., Needham, D. M., Oh, E. S., Wilson, L. M., Nikooie, R., Zhang, A., Koneru, M., Balagani, A., Singu, S., Aldabain, L., & Robinson, K. A. (2019). Antipsychotics for the Prevention and Treatment of Delirium. https://doi.org/10.23970/ahrqepccer219
528. Newhouse, A., Buch, K., & Chemali, Z. (2020). Dementia Unspecified. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.19nr02570
529. Nielsen, J. F., Klemar, B., Hansen, H., & Sinkjær, T. (1995). A new treatment of spasticity with repetitive magnetic stimulation in multiple sclerosis.. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.58.2.254-a
530. Niesink, R. J., & Laar, M. V. (2013). Does Cannabidiol Protect Against Adverse Psychological Effects of THC?. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2013.00130
531. Nigg, J. T., Butler, K. M., Huang‐Pollock, C., & Henderson, J. M. (2002). Inhibitory processes in adults with persistent childhood onset ADHD.. Journal of Consulting and Clinical Psychology. https://doi.org/10.1037/0022-006x.70.1.153
532. Noble, F., & Roques, B. P. (2003). Inhibitors of Enkephalin Catabolism. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_5
533. Noel, N., Seibell, P., Nadeau, J., & Storch, E. (2016). Treating just-right symptoms in geriatric obsessive-compulsive disorder. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.196700
534. Norton, C., Williams, J., Taylor, C., Nunwa, A., & Whayman, K. (2008). Chapter 19 Bowel care and vulnerable groups. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199298655.003.0019
535. Ns, M., & Gold, M. S. (1990). The contemporary alcoholic.. PubMed.
536. Nubukpo, P., Laot, L., & Clément, J. (2012). Addictive behaviors in the aged. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2012.0355
537. Nunes, E. V., Deliyannides, D. A., Donovan, S. J., & McGrath, P. J. (1996). THE MANAGEMENT OF TREATMENT RESISTANCE IN DEPRESSED PATIENTS WITH SUBSTANCE USE DISORDERS. Psychiatric Clinics of North America. https://doi.org/10.1016/s0193-953x(05)70290-2
538. Nunes, J. T., Brigadeiro, D., Andrade, J., & Costa, A. P. D. (2017). Neuroleptic-induced Parkinsonism in Patient with Obsessive Compulsive Disorder: A Case Report. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.1063
539. Ogbonna, C. I., & Lembke, A. (2017). Tapering Patients Off of Benzodiazepines.. PubMed.
540. Olmos-López, A., Ibarra-Aguilar, J., Cornelio-Nieto, J. O., Ocaña-Hernández, L. A., Márquez-Amaya, M. A., Luna-López, N. A., Reséndiz-Aparicio, J. C., & Rodríguez‐Leyva, I. (2019). Clinical guideline: status epilepticus in children and adults. DELETED. https://doi.org/10.24875/rmn.m19000031
541. Olsson, S. (2015). Missnöjet pyr över svensk häktestortyr - En undersökning av det kritiserade häktningsinstitutet.
542. Omari, F. E., Berrada, H., Chebli, H., & Azraf, F. (2023). Depressive disorder comorbid with problematic alcohol use. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1374
543. Onda, K., Yukawa, T., Sakaue, M., Tsuboya, R., Inoue, E., & Someya, T. (2021). Withdrawal from long‐term use of caffeinated drinks can cause schizophrenia‐like symptoms: A case report. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13199
544. Ornoy, A. (2002). The effects of alcohol and illicit drugs on the human embryo and fetus.. PubMed.
545. Osborn, C. J., & Iarussi, M. M. (2017). Addictions Counseling. Routledge eBooks. https://doi.org/10.4324/9781315537061-13
546. Oslin, D. W. (2007). Addictions. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-960-8_9
547. Oster, E., Čudina, N., Pavasović, H., Crnić, A. P., Božić, F., Fadel, C., & Gıorgı, M. (2023). Intoxication of dogs and cats with common stimulating, hallucinogenic and dissociative recreational drugs. Veterinary and Animal Science. https://doi.org/10.1016/j.vas.2023.100288
548. Otsuka, K., Kato, S., Abe, T., SUGIYAMA, H., Watanabe, Y., Kobayashi, T., & Okajima, Y. (2002). [Classification of long-term clinical course of 'atypical psychosis': a 20-year follow-up study at a medical school hospital].. PubMed.
549. Ouslander, J. G. (1981). Drug Therapy in the Elderly. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-95-6-711
550. Outhoff, K. (2016). Cognitive enhancement : a brief overview : review. South African Family Practice.
551. Outhoff, K. (2016). Cognitive enhancement: a brief overview. South African Family Practice. https://doi.org/10.4102/safp.v58i1.4436
552. O’Brien, C. P. (1994). Treatment of alcoholism as a chronic disorder. Birkhäuser Basel eBooks. https://doi.org/10.1007/978-3-0348-7330-7_35
553. O’Brien, C. P. (2005). Benzodiazepine use, abuse, and dependence.. PubMed.
554. Page, R. M. (2014). Substance Abuse and Adolescent Psychological Distress. The Wiley Blackwell Encyclopedia of Health, Illness, Behavior, and Society. https://doi.org/10.1002/9781118410868.wbehibs433
555. Pais, S. C., Menezes, I., & Nunes, J. A. (2016). From Normative to Deviant Behaviour: Health and Illness Definitions Related to Children and Adolescents’ Perspectives. BRILL eBooks. https://doi.org/10.1163/9781848884885_004
556. Pal, H., Kumar, R., Bhushan, S., & Berry, N. (2005). Psychiatric co-morbidity associated with pheniramine abuse and dependence. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.46079
557. Panahi, S., & Tremblay, A. (2018). Sedentariness and Health: Is Sedentary Behavior More Than Just Physical Inactivity?. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2018.00258
558. Pang, D., & Pucci, M. (2021). Medical Aspects of Drug and Alcohol Use. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623199.011
559. Pannill, F. C. (1987). Urinary Incontinence1. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.1987.tb02342.x
560. Paraschakis, A., & Konstantinidou, D. (2012). P-664 - Stalking of psychiatrists by their patients: an unsettling reality. European Psychiatry. https://doi.org/10.1016/s0924-9338(12)74831-9
561. Parolaro, D., Viganò, D., & Rubino, T. (2005). Endocannabinoids and Drug Dependence. Current Drug Targets - CNS & Neurological Disorders. https://doi.org/10.2174/156800705774933014
562. Parrott, A. C. (2006). MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. Journal of Psychopharmacology. https://doi.org/10.1177/0269881106063268
563. Parsa, A., Mohammadkhan, A., & Babaeian, M. (2017). Zolpidem-Induced Narcolepsy, Faint, Seizure or Coma? A Case Report. Case Reports in Clinical Medicine. https://doi.org/10.4236/crcm.2017.62004
564. Parsons, O. A. (1987). Intellectual impairment in alcoholics: Persistent issues. Acta Medica Scandinavica. https://doi.org/10.1111/j.0954-6820.1987.tb13040.x
565. Patel, A. I., Yadav, A., Patel, A. B., & Vyas, A. J. (2023). Post Covid-19 Women Complications. Asian Journal of Nursing Education and Research. https://doi.org/10.52711/2349-2996.2023.00017
566. Patel, A., & Patel, K. (2016). A Case of Childhood Onset Obsessive Compulsive Disorder Presented as School Refusal for a Year. International Journal of Indian Psychology. https://doi.org/10.25215/0401.012
567. Patel, A., Moreland, T., Haq, F., Siddiqui, F., Mikul, M., Qadir, H., & Raza, S. (2011). Persistent Psychosis After a Single Ingestion of “Ecstasy” (MDMA). The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01200
568. Paul, M. A., & Teli, B. A. (2020). ADHD and Substance Abuse in Children and Adolescents. Advances in medical diagnosis, treatment, and care (AMDTC) book series. https://doi.org/10.4018/978-1-7998-5495-1.ch014
569. Payne‐James, J., Perera, C., & Aggrawal, A. (2023). Neglect. CRC Press eBooks. https://doi.org/10.1201/9781003138754-54
570. Peacey, J., Miller, H., Huthwaite, M., & Romans, S. (2011). Sleep Medication in Acute Psychiatric Illness. The Journal of Nervous and Mental Disease. https://doi.org/10.1097/nmd.0b013e31823e6552
571. Pearlson, G. D. (2020). Psychology + human behavior. Weed Science. https://doi.org/10.1016/b978-0-12-818174-4.00006-9
572. Pechnick, R. N., Cunningham, K. A., & Danovitch, I. (2014). Hallucinogen-Related Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg51
573. Peele, S. (2001). Is Gambling an Addiction Like Drug and Alcohol Addiction?: Developing Realistic and Useful Conceptions of Compulsive Gambling. Journal of Gambling Issues. https://doi.org/10.4309/jgi.2001.3.2
574. Peniston, J. H. (2012). A Review of Pharmacotherapy for Chronic Low Back Pain with Considerations for Sports Medicine. The Physician and Sportsmedicine. https://doi.org/10.3810/psm.2012.11.1985
575. Penn, M., & Goldstein, D. (2005). The Role of Hunger and Satiety in Weight Management. Humana Press eBooks. https://doi.org/10.1385/1-59259-865-x:307
576. Pereira, S. M. P., Guimarães, S. K. G., Marques, A., & Borges, S. (2008). Electroconvulsivotherapy in the elderly, indications, risks and side-effects. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2008.01.611
577. Perera-Diltz, D. (2015). Cannabis Use Disorder. https://doi.org/10.63134/refd7106
578. Pergolizzi, J. V., Annabi, H., Gharibo, C., & LeQuang, J. A. (2018). The Role of Lofexidine in Management of Opioid Withdrawal. Pain and Therapy. https://doi.org/10.1007/s40122-018-0108-7
579. Petit, J., & Sansone, R. A. (2011). A Case of Interdose Discontinuation Symptoms With Venlafaxine Extended Release. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01140
580. Petruševičienė, D., & Kriščiūnas, A. (2003). [Occupational therapy for patients after stroke].. PubMed.
581. Peña, M. A. M. (2013). Síndrome de sobreentrenamiento. IATREIA.
582. Phillips, M. M. (1990). The Alcohol Drinking History.
583. Pierce, D. M. (1973). Differences in “Flashbacks” Unrelated to Specific Drugs. Journal of Drug Issues. https://doi.org/10.1177/002204267300300410
584. Pies, R. W. (2007). Is It Bipolar Depression? 'WHIPLASHED' Aids Diagnosis. Current psychiatry.
585. Pinheiro, M., Pais, J., & Cabral, T. (2015). Consumption of Cocaine Once – Trigger of Psychosis in a Consumer Hashish – Clinical Case. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)30390-4
586. Pitel, A., & Segobin, S. (2023). Contribution of Thalamocortical Loops to the Development, Persistence, and Complications of Alcohol Use Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197676158.003.0069
587. Piwuna, C. G., Makput, D. M., & Wakil, M. A. (2015). Persistent delusional disorder in a 32 year old male. Highland Medical Research Journal.
588. Piątek, A., Koziarska-Rościszewska, M., & Zawilska, J. B. (2015). Rekreacyjne używanie leków dostępnych w odręcznej sprzedaży: odurzanie i doping mózgu. Alcoholism and Drug Addiction. https://doi.org/10.1016/j.alkona.2015.03.001
589. Poirier, M. F., & Ginestet, D. (1995). [Drugs diverted from reaching drug addicts].. PubMed.
590. Popa, T., & Delcea, C. (2019). Voyeurism and Scopophilia. International Journal of Advanced Studies in Sexology. https://doi.org/10.46388/ijass.2019.12.11.121
591. Pope, H. G., McElroy, S. L., Keck, P. E., Hudson, J. I., Faedda, G. L., & Swann, A. C. (1992). Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. American Journal of Psychiatry. https://doi.org/10.1176/ajp.149.12.1633
592. Portenoy, R. K., & Bruera, É. (2003). Clinical Trials of Antiemetics in the Palliative Care Setting: Research Issues. Oxford University Press eBooks. https://doi.org/10.1093/acprof:oso/9780195130652.003.0005
593. Porter, T., & Feldman, M. D. (2011). A Case of Factitious Pedophilia. Journal of Forensic Sciences. https://doi.org/10.1111/j.1556-4029.2011.01804.x
594. Post, R. M., & Leverich, G. S. (2007). The Role of Psychosocial Stress in the Onset and Progression of Bipolar Disorder and its Comorbidities: The Need for Earlier and Alternative Modes of Therapeutic Intervention. FOCUS The Journal of Lifelong Learning in Psychiatry. https://doi.org/10.1176/foc.5.1.73
595. Potocka‐Banaś, B., Majdanik, S., Korwin-Piotrowska, K., Dembińska, T., Janus, T., & Borowiak, K. (2013). [Overdosing of popular medicines available without a prescription, a new trend among teenagers].. PubMed.
596. Powell, A., Yamaguchi, N., Lu, H., Pareek, O., Elman, I., Gold, M. S., Pinhasov, A., Blum, K., & Thanos, P. K. (2025). The Role of Fatty Acid Binding Proteins in Neuropsychiatric Diseases: A Narrative Review. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl26812
597. Prabha, Y. S. (2023). Stress as a Topic of Concern in Gut Health: A Review. UTTAR PRADESH JOURNAL OF ZOOLOGY. https://doi.org/10.56557/upjoz/2023/v44i123527
598. Prathima, P. R., Johnson, D. B., Suresh, R., Venkatnarayanan, R., & Ahammad, P. M. A. (2013). Acute and Subacute Toxicity study of Milnacipran Hydrochloride in Wistar rats by Oral Route. Research Journal of Pharmacology and Pharmacodynamics.
599. Preuss, U. W., Wong, W., & Farren, C. K. (2014). Chapter 9: Bipolar Affective Disorders and Alcohol Dependence: Comorbidity, Consequences Consequences, and Treatment.
600. Preziosi, T. J., Starkstein, S. E., Bolduc, P. L., & ROBINSON, R. G. (1990). Depression in Parkinson??s Disease. The Journal of Nervous and Mental Disease. https://doi.org/10.1097/00005053-199001000-00005
601. Prvčić, I., Zec, M. R., & Barišić, I. (2008). Psychological aspects of learning disabilities. Paediatria Croatica. https://doi.org/10.13112/pc.925
602. Pugliese, M., Rossi, C., Guidotti, I., Gallo, C., Casa, E. D., Bertoncelli, N., Coccolini, E., & Ferrari, F. (2013). Preterm birth and developmental problems in infancy and preschool age Part II: cognitive, neuropsychological and behavioural outcomes. The Journal of Maternal-Fetal & Neonatal Medicine. https://doi.org/10.3109/14767058.2013.794205
603. Pulia, M. S., & Richmond, J. S. (2013). The patient with post-traumatic stress disorder in the emergency department. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139088077.016
604. Pérez‐Mañá, C., Papaseit, E., Fonseca, F., Farré, A., Torrens, M., & Farré, M. (2018). Drug Interactions With New Synthetic Opioids. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2018.01145
605. Pétursson, H. (1994). The benzodiazepine withdrawal syndrome. Addiction. https://doi.org/10.1111/j.1360-0443.1994.tb03743.x
606. Qamar, A., Kotha, K., & Ioachimescu, O. C. (2011). Obstructive Sleep Apnea. BENTHAM SCIENCE PUBLISHERS eBooks. https://doi.org/10.2174/978160805267711101010021
607. Queiroz, A. P. D. S., Pedro, M. O. P., Campos, M. W., Torales, J., Ventriglio, A., & Castaldelli-Maia, J. M. (2025). Cognitive Effects of Cannabis Use: A Comprehensive Review Across Domains. Neurology International. https://doi.org/10.3390/neurolint17070107
608. Rader, R. K., McCauley, L., & Callen, E. C. (2009). Current strategies in the diagnosis and treatment of childhood attention-deficit/hyperactivity disorder.. PubMed.
609. Radhakrishnan, R., Wilkinson, S. T., & Dâ€TMSouza, D. C. (2014). Gone to Pot â€“ A Review of the Association between Cannabis and Psychosis. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2014.00054
610. Radmanović, M. B., & Burgić, S.-S. (2020). Comorbidity in Children and Adolescents with ADHD. IntechOpen eBooks. https://doi.org/10.5772/intechopen.94527
611. Raffelt, A., Kerry, J., & Matthew, R. A. (2011). Evaluation of Tinnitus in the Emergency Department. InTech eBooks. https://doi.org/10.5772/27582
612. Rajesh, M., & Kumar, C. P. G. (2014). Influence of interactional relationship on stress among women executives in software company in Chennai. EXCEL International Journal of Multidisciplinary Management Studies.
613. Raju, V., & Muthulakshmi, G. (2014). Impact of stress in work life balance among working people. South Asian Journal of Marketing & Management Research.
614. Rakofsky, J. J., & Dunlop, B. W. (2014). Treating Bipolar Mania in the Outpatient Setting: Enlist the Help of Family, Employ Evidence-Based Pharmacologic and Psychotherapeutic Strategies. Current psychiatry.
615. Ramchandani, V. A., Slattum, P. W., Patkar, A. A., Wu, L., Lee, J., Mohanty, M., Coe, M. A., & Li, T. (2014). Psychopharmacology and the Consequences of Alcohol and Drug Interactions. https://doi.org/10.1002/9781118430965.ch12
616. Ramesh, D., Schlosburg, J. E., Wiebelhaus, J. M., & Lichtman, A. H. (2011). Marijuana Dependence: Not Just Smoke and Mirrors. ILAR Journal. https://doi.org/10.1093/ilar.52.3.295
617. Rani, S., & Saini, D. S. (2015). Organizational Stress in Relation to Job Satisfaction and General Health of Professional Women. International journal of education and management studies.
618. Rao, T. S. (2018). Psychosocial therapies in addictive disorders. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.224346
619. Rao, T. S., & Kumar, M. A. (2008). Agenda for specialty section in addiction medicine. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.44741
620. Rapacz, A. (2018). ADVANCES AND LIMITATIONS IN PHARMACOTHERAPY OF EPILEPSY. Acta Poloniae Pharmaceutica - Drug Research. https://doi.org/10.32383/appdr/83591
621. RAPOPORT, J. L., & Fiske, A. P. (1998). The New Biology Of Obsessive-Compulsive Disorder: Implications for Evolutionary Psychology. Perspectives in biology and medicine. https://doi.org/10.1353/pbm.1998.0063
622. Rastegar, D. A., & Fingerhood, M. (2015). Cocaine, Methamphetamine, and Other Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0008
623. Rastegar, D. A., & Fingerhood, M. (2015). Hallucinogens and Dissociatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0009
624. Rastegar, D. A., & Fingerhood, M. (2015). Marijuana and Other Cannabinoids. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0010
625. Reddy, S., Elsayem, A., & Talukdar, R. (2005). Palliative Care. CRC Press eBooks. https://doi.org/10.1201/b14119-59
626. Ree, J. M. V., Koob, G. F., Higgins, G. A., Naranjo, C. A., & Zvartau, E. (1995). Neurohormonal Systems Underlying Drug Addiction: Relevance for Treatment Strategies. Birkhäuser Basel eBooks. https://doi.org/10.1007/978-3-0348-7218-8_27
627. Reid, W. H., Balis, G. U., & Sutton, B. (1997). The treatment of psychiatric disorders : revised for DSM-IV.
628. Renault, P. F., Hoofnagle, J. H., Park, Y., Mullen, K. D., Peters, M. G., Jones, D. B., Rustgi, V. K., & Jones, E. A. (1987). Psychiatric Complications of Long-term Interferon Alfa Therapy. Archives of Internal Medicine. https://doi.org/10.1001/archinte.1987.00370090055011
629. Rengifo, C. A. (2014). Estudio de caso: Trastorno Obsesivo-Compulsivo. Revista de Investigación Universitaria. https://doi.org/10.17162/riu.v3i2.519
630. Rg, A., & Rareshide, E. (1989). Disorders of taste.. PubMed.
631. Riaz, A., Shahid, Q., Yousaf, H. M., Gul, U., Shah, S. S., Hidayat, A., Hamid, T., Rahman, A. U., Usman, M., Khan, M. K., Muhtiar, R., & Khalid, B. (2024). Mirtazapine in Primary Insomnia: Case report and Literature review. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2024.23.1.2213
632. Riccio, C. A., Pliego, J., & Rae, W. A. (2016). Mind-body approaches and chronic illness: Status of research. International Journal of School & Educational Psychology. https://doi.org/10.1080/21683603.2016.1130544
633. Riddle, M. A., King, R. A., Hardin, M. T., Scahill, L. D., Ort, S. I., Chappell, P., Rasmusson, A. M., & Leckman, J. F. (1990). Behavioral Side Effects of Fluoxetine in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.1990.1.193
634. Risse, S. C., & Barnes, R. (1986). Pharmacologic Treatment of Agitation Associated With Dementia. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.1986.tb04320.x
635. Roberts, A. R., & Yeager, K. R. (2009). Indicators of a Crisis-Prone Person. https://doi.org/10.1093/oso/9780195382907.003.0004
636. Robertson, S., Peacock, E. E., & Scott, R. M. (2023). Benzodiazepine Use Disorder: Common Questions and Answers.. PubMed.
637. Rodriguez, C. P., Dodds, T., & Suzuki, J. (2017). Addiction. Pain Medicine. https://doi.org/10.1007/978-3-319-43133-8_33
638. Rodríguez, E. O., Esquivel, P. S., & Triana, I. M. (2024). Un panorama actualizado de la dispepsia. Revista médica de Panamá. https://doi.org/10.37980/im.journal.rmdp.20242296
639. Rodríguez, F. D., Sánchez, M. L., & Coveñas, R. (2023). Neurotensin and Alcohol Use Disorders: Towards a Pharmacological Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24108656
640. Roessner, V., & Rothenberger, A. (2014). Tic Disorders. https://doi.org/10.1007/978-3-7091-1501-5_27
641. Romero‐Sandoval, E. A. (2011). Depression and Pain. Anesthesiology. https://doi.org/10.1097/aln.0b013e31822ec185
642. Ron, M. A. (1986). Volatile Substance Abuse: A Review of Possible Long-Term Neurological, Intellectual and Psychiatric Sequelae. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.148.3.235
643. Ronad, S. V., Patail, C. S., Gondbal, S. H., TC, K., Ronad, M., Pankaja, T., Badesgol, R., & Singhal, P. K. J. (2019). Professionals in metro cities suffer from anxiety disorder. Nursing & Care Open Access Journal. https://doi.org/10.15406/ncoaj.2019.06.00198
644. Roth, T., Krystal, A. D., & Lieberman, J. A. (2007). Long-term issues in the treatment of sleep disorders.. CNS Spectrums.
645. Rowbotham, M. C., & Lowenstein, D. H. (1990). Neurologic Consequences of Cocaine Use. Annual Review of Medicine. https://doi.org/10.1146/annurev.me.41.020190.002221
646. Rowe, P. C., Underhill, R., Friedman, K. J., Gurwitt, A., Medow, M. S., Schwartz, M., Speight, N., Stewart, J. M., Vallings, R., & Rowe, K. S. (2017). Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer. Frontiers in Pediatrics. https://doi.org/10.3389/fped.2017.00121
647. Roy, A. (1996). Aetiology of Secondary Depression in Male Alcoholics. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.169.6.753
648. Roy, B. A. (2015). Overreaching/Overtraining. ACSMʼs Health & Fitness Journal. https://doi.org/10.1249/fit.0000000000000100
649. Rucci, J. M., & Feinstein, R. E. (2014). Neurocognitive Disorders and Mental Disorders Due to Another Medical Condition. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199326075.003.0005
650. Ruiz, C. B., Torralbo, M. B., Garcia, R. R., Llobet, A. H., Fernández, I. A., Nielsen, N. P., Landeo, A. R., Ramírez, M. M., Fuentes, D. G., Soler, M. A., & Cañete, J. (2020). Psicosis dual y cariprazina. Caso clínico. LIBRO COMUNICACIONES. https://doi.org/10.17579/sepd2020p141
651. Ruiz, P., Strain, E. C., & Langrod, J. (2007). The Substance Abuse Handbook.
652. Ryan, K. K. (2009). Effects of Acute Nicotine on Risk Taking in Individuals with Attention-Deficit/Hyperactivity Disorder and Age-Matched Controls.
653. Río, J. A. D. (2013). Incapacitación y drogodependencias.
654. Sabo-Graham, T., & Seay, A. R. (1998). Consultation with the Specialist: Management of Status Epilepticus in Children. Pediatrics in Review. https://doi.org/10.1542/pir.19.9.306
655. Sadikin, A., & Linda, N. (2018). PENYALAHGUNAAN NARKOBA DAN PSIKOTROPIKA DI KALANGAN REMAJA.
656. Sahakian, B. J., & Morein‐Zamir, S. (2011). Depression and resilience: insights from cognitive, neuroimaging, and psychopharmacological studies. Oxford University Press eBooks. https://doi.org/10.1093/acprof:oso/9780199600434.003.0023
657. Saini, S., Shandil, A., & S.K., E. (2012). Recent Therapies in Depression. InTech eBooks. https://doi.org/10.5772/33335
658. Salani, D., Goldin, D., Valdes, B., & Santis, J. P. D. (2023). The Price of Gambling: Examining Gambling Disorders. Issues in Mental Health Nursing. https://doi.org/10.1080/01612840.2023.2232862
659. Santana, L., Jeremias, D., Braga, F. I. L., Mesquita, B., & Santos, C. P. (2024). Binge, Purge, and Wander: Navigating Bulimia and Attention Deficit Hyperactivity Disorder (ADHD). Cureus. https://doi.org/10.7759/cureus.69076
660. Santos, M. G. (2023). Adult ADHD: 6 studies of pharmacologic interventions. Current psychiatry. https://doi.org/10.12788/cp.0344
661. Sarkar, S., Bhatia, G., & Dhawan, A. (2023). Clinical Practice Guidelines for Assessment and Management of Patients with Substance Intoxication Presenting to the Emergency Department. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_490_22
662. Sarris, J., O’Neil, A., Coulson, C., Schweitzer, I., & Berk, M. (2014). Lifestyle medicine for depression. BMC Psychiatry. https://doi.org/10.1186/1471-244x-14-107
663. Sayyah, M., Majzoob, S., & Sayyah, M. (2013). Metabolic and toxicological considerations for obsessive–compulsive disorder drug therapy. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425255.2013.783011
664. Scala, M., Biondi, L., Serretti, A., & Fabbri, C. (2023). Obsessive-Compulsive, Psychotic, and Autism Dimensions Overlap in Real World: A Case Report. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0000000000000561
665. Schepis, T. S., Rao, U., Yadav, H., & Adinoff, B. (2011). The Limbic-Hypothalamic-Pituitary-Adrenal Axis and the Development of Alcohol Use Disorders in Youth. Alcoholism Clinical and Experimental Research. https://doi.org/10.1111/j.1530-0277.2010.01380.x
666. Schildkrout, B. (2014). Delirium. https://doi.org/10.1002/9781394260447.ch2
667. Schildkrout, B. (2014). Disease #34: Mercury Poisoning. https://doi.org/10.1002/9781394260447.ch62
668. Schmitz, N., & Wu, H. S. (2015). Advances in the Treatment of Secondary CNS Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.63.1143
669. Schneier, F. R., Bruce, L. C., & Heimberg, R. G. (2014). Social Anxiety Disorder (Social Phobia). American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg18
670. Schneir, A., & Clark, R. F. (2007). The Role of Illicit Drug Use in Sudden In-Custody Death. Humana Press eBooks. https://doi.org/10.1007/978-1-59745-015-7_6
671. Schrör, K. (2016). Toxicity and Drug Safety. https://doi.org/10.1002/9783527685059.ch3
672. Schuckit, M. A. (1996). Alcohol, Anxiety, and Depressive Disorders.. PubMed.
673. Schulman, E. A. (2011). Abuse and Maltreatment: Their Effect on Headache. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2011.02020.x
674. Schwartz, R. H. (1984). Psychoactive Drug Use During Adolescence: The Pediatrician's Role. Archives of Pediatrics and Adolescent Medicine. https://doi.org/10.1001/archpedi.1984.02140400083021
675. Schweitzer, J. B. (2010). Attention‐Deficit/Hyperactivity Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0096
676. Scott, S., & Palmer, M. (2020). Conduct disorders and antisocial personality disorder in childhood and adolescence. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198713005.003.0124
677. Scuvée‐Moreau, J. (2013). [Neurobiology of addiction].. PubMed.
678. Seim, L. A., Vijapura, P., Pagali, S. R., & Burton, M. C. (2020). Common substance use disorders in older adults. Hospital Practice. https://doi.org/10.1080/21548331.2020.1733287
679. Sejdić, E., Malandraki, G. A., & Coyle, J. L. (2018). Computational Deglutition: Using Signal- and Image-Processing Methods to Understand Swallowing and Associated Disorders [Life Sciences]. IEEE Signal Processing Magazine. https://doi.org/10.1109/msp.2018.2875863
680. Sevarino, K. A., & Shelby, B. C. (2015). Stimulant Use Disorders. Psychiatry. https://doi.org/10.1002/9781118753378.ch80
681. Shah, R. K., & Baum, C. R. (2018). Synthetic drug intoxication in children: recognition and management in the emergency department.. PubMed.
682. Shah, R. R. (2005). Mechanistic basis of adverse drugreactions: the perils of inappropriate dose schedules. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.4.1.103
683. Shaikh, S., & Lakshmi, R. (2014). Delayed awakening after anaesthesia- A challenge for an anaesthesiologist. International Journal of Biomedical and Advance Research. https://doi.org/10.7439/ijbar.v5i8.829
684. Shakhar, K., & Fleisig, D. (2013). How to Cope with Stress and Depression in Women with Recurrent Miscarriage. https://doi.org/10.1002/9781118749012.ch13
685. Sharma, A. K., Rani, E., Waheed, A., & Rajput, S. K. (2015). Pharmacoresistant Epilepsy: A Current Update on Non-Conventional Pharmacological and Non-Pharmacological Interventions. Journal of Epilepsy Research. https://doi.org/10.14581/jer.15001
686. Sharma, S., Nepal, B., Moon, C. S., Chabenne, A., Khogali, A., Ojo, C., Hong, E., Gaudet, R., Sayed-Ahmad, A., Jacob, A., Murtuza, M., & Firlit, M. L. (2014). Psychology of Craving. Open Journal of Medical Psychology. https://doi.org/10.4236/ojmp.2014.32015
687. Sharp, C. W., Rosenberg, N. L., & Beauvais, F. (2008). Substance Abuse: Inhalant‐Related Disorders. Psychiatry. https://doi.org/10.1002/9780470515167.ch61
688. Sharp, L. K., & Lipsky, M. S. (2002). Screening for depression across the lifespan: a review of measures for use in primary care settings.. PubMed.
689. Sheets, E. S., & Brosse, A. L. (2010). Major Depressive Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0522
690. Shields, L. B. E., Rolf, C. M., & Hunsaker, J. C. (2015). Sudden Death Due To Acute Cocaine Toxicity—Excited Delirium in a Body Packer. Journal of Forensic Sciences. https://doi.org/10.1111/1556-4029.12860
691. Shinohara, R. C., Inoue, K., Takayanagi, S., Furutaka, Y., Yamazaki, H., & Watanabe, S. (2025). Successful treatment with lithium carbonate for periodic psychosis of adolescence. Psychiatry and Clinical Neurosciences Reports. https://doi.org/10.1002/pcn5.70133
692. Shirley, E. A., Hudspeth, L. J., & Maynard, J. R. (2018). Managing Sports-related Concussions From Time of Injury Through Return to Play. Journal of the American Academy of Orthopaedic Surgeons. https://doi.org/10.5435/jaaos-d-16-00684
693. Shirley, K. L., Norelli, L. J., & Smith, H. S. (2008). “Impulsology” <i>A New Paradigm for Addiction</i>. https://doi.org/10.1093/oso/9780195300550.003.0013
694. Shkembi, A., Skenderi, E., Imeraj, F., Kuneshka, N., Xhelili, G., & Durma, A. (2023). A case of sexual abuse and art therapy. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2023.18.1.0566
695. Shou-zh, W. (2008). Drug Psychosis by Antipsychotic Drugs:Report of 40 Cases. Zhongguo quanke yixue.
696. Shulman, M., Greiner, M., & Bisaga, A. (2023). Commentary on Foot <i>et al</i>.: Clinical considerations in addressing comorbid stimulant use in opioid use disorder. Addiction. https://doi.org/10.1111/add.16374
697. Silver, R. M., & Airoldi, J. (2016). 27. Inherited thrombophilia. CRC Press eBooks. https://doi.org/10.1201/9781315200910-28
698. Silverglat, M. J. (1981). Baclofen and Tricyclic Antidepressants: Possible Interaction. JAMA. https://doi.org/10.1001/jama.1981.03320150019012
699. Sinha, R. (2018). Stress and Addiction. Routledge eBooks. https://doi.org/10.4324/9781315689197-25
700. Smith, B. H., Molina, B. S. G., & Pelham, W. E. (2002). The Clinically Meaningful Link Between Alcohol Use and Attention Deficit Hyperactivity Disorder.. Alcohol Research & Health.
701. Smith, K. M., Larive, L. L., & Romanelli, F. (2002). Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/59.11.1067
702. Smith, P. F. (2005). The safety of cannabinoids for the treatment of multiple sclerosis. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.4.3.443
703. Snaith, P. (1994). Anxiety Control Training. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.1.2.57
704. So, E. L., & Penry, J. K. (1981). Adverse Effects of Phenytoin on Peripheral Nerves and Neuromuscular Junction: A Review. Epilepsia. https://doi.org/10.1111/j.1528-1157.1981.tb06157.x
705. Solimini, R., Rotolo, M. C., Pichini, S., & Pacifici, R. (2017). Neurological Disorders in Medical Use of Cannabis: An Update. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527316666170413105421
706. Sommer, I. E., & Arango, C. (2017). Moving interventions from after to before diagnosis. World Psychiatry. https://doi.org/10.1002/wps.20454
707. Soutullo, C. A., Are, F., & Schield-Grant, S. (2023). [Factors associated with adherence to pharmacological treatment of attention deficit hyperactivity disorder (ADHD): preliminary review].. PubMed.
708. Soysal, P., & Işık, A. T. (2014). Hypoactive Delirium Caused by Pulmonary Embolus in an Elderly Adult. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.12720
709. Spanagel, R., Tran, B. X., Reyes‐Gibby, C. C., DeBeck, K., Ibrahim, F., & Bonevski, B. (2016). Advances in Drug Addiction.
710. Spier, S. A. (1995). Toxicity and Abuse of Prescribed Stimulants. The International Journal of Psychiatry in Medicine. https://doi.org/10.2190/kw49-885p-ea82-k6k3
711. Sriramoju, M., Keerthi, V. P., Alumdri, D. B., & Akula, S. (2014). Evaluation of antidepressant activity of ethanolic and aqueous extract of Solanum tuberosum peel. Journal of Comprehensive Pharmacy. https://doi.org/10.37483/jcp.2014.1503
712. Starace, F., & Sherr, L. (1998). Suicidal behaviours, euthanasia and AIDS. AIDS. https://doi.org/10.1097/00002030-199804000-00001
713. Stephen, S., & Bailey, C. (2013). Managing disruptive behaviour disorders in children.. PubMed.
714. Stewart, S. M. (2013). Depression. The Encyclopedia of Cross‐Cultural Psychology. https://doi.org/10.1002/9781118339893.wbeccp158
715. Stone, J., Carson, A., & Sharpe, M. (2005). Functional symptoms in neurology: management. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2004.061663
716. Stone, J., Pal, S., Blackburn, D., Reuber, M., Thekkumpurath, P., & Carson, A. (2015). Functional (Psychogenic) Cognitive Disorders: A Perspective from the Neurology Clinic. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-150430
717. Strassman, R. J. (1984). ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE. The Journal of Nervous and Mental Disease. https://doi.org/10.1097/00005053-198410000-00001
718. Strassnig, M., & Harvey, P. D. (2013). Treatment of obesity and disability in schizophrenia.. PubMed.
719. Stratakis, C. A., Gold, P. W., & Chrousos, G. P. (1995). Neuroendocrinology of Stress: Implications for Growth and Development. Hormone Research. https://doi.org/10.1159/000184269
720. Stringer, J. D. (2016). Gender and Sexual Health: Sexual Dysfunction.. PubMed.
721. Stubbe, D. (2007). Child and adolescent psychiatry : a practical guide. Lippincott Williams & Wilkins eBooks.
722. Suchowersky, O., Reich, S. G., Perlmutter, J. S., Zesiewicz, T., Gronseth, G., & Weiner, W. J. (2006). Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) [RETIRED]. Neurology. https://doi.org/10.1212/01.wnl.0000215437.80053.d0
723. Sullivan, M. A., & RUDNIK‐LEVIN, F. (2001). Attention Deficit/Hyperactivity Disorder and Substance Abuse. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2001.tb05783.x
724. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. JBI Library of Systematic Reviews. https://doi.org/10.11124/jbisrir-2010-726
725. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/01938924-201008341-00020
726. Szkodny, L. E., Jacobson, N. C., Llera, S. J., & Newman, M. G. (2014). Generalized Anxiety Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg19
727. Tacn, A. (2012). PTSD in the Context of Malignant Disease. InTech eBooks. https://doi.org/10.5772/27424
728. Takahashi, A., & Franklin, J. (1996). Alcohol Abuse. Pediatrics in Review. https://doi.org/10.1542/pir.17-2-39
729. Takahashi, A., & Franklin, J. (1996). Alcohol Abuse. Pediatrics in Review. https://doi.org/10.1542/pir.17.2.39
730. Talley, N. J. (2008). Commentary: Controversies in NICE guidance on irritable bowel syndrome. BMJ. https://doi.org/10.1136/bmj.39504.409329.ad
731. Taoufiq, P. I. (2024). Cognitive behavioral therapy for a case of addiction with personality disorder (clinical case study). ARID International Journal of Social Sciences and Humanities. https://doi.org/10.36772/arid.aijssh.2024.s.69
732. Taylor, S. M., & Beckmann, D. (2021). An adolescent with new-onset inattention. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0028
733. Teixeira, M. Z. (2013). Rebound effects of modern drugs: serious adverse events unknown by health professionals. Revista da Associação Médica Brasileira (English Edition). https://doi.org/10.1016/s2255-4823(13)70530-7
734. Tharani, Z., Musaddique, A., & Qutb, S. H. (2023). Burnout and its impact on Nurses and Doctors. Journal of the Pakistan Medical Association. https://doi.org/10.47391/jpma.23-69
735. Thibault, J. M., O’Brien, J. G., & Turner, L. (1999). Indirect Life-Threatening Behavior in Elderly Patients. Journal of Elder Abuse & Neglect. https://doi.org/10.1300/j084v11n02_02
736. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. DeckerMed Family Medicine. https://doi.org/10.2310/fm.13043
737. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. https://doi.org/10.2310/cannabis.13043
738. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. https://doi.org/10.2310/psych.13043
739. Tiglao, S. M., Meisenheimer, E. S., & Oh, R. (2021). Alcohol Withdrawal Syndrome: Outpatient Management.. American family physician.
740. Tiscione, N. B., & Rohrig, T. P. (2021). 1,1-Difluoroethane Forensic Aspects for the Toxicologist and Pathologist. Journal of Analytical Toxicology. https://doi.org/10.1093/jat/bkab054
741. Tito, E., Knapp, B., Bucca, A., & Espiridion, E. D. (2019). A Case Report of Schizoaffective Disorder with Pseudoseizures in a 42-year-old Male. Cureus. https://doi.org/10.7759/cureus.4835
742. Tollefson, G. D., Rampey, A. H., Potvin, J. H., Jenike, M. A., Rush, A. J., Dominguez, R. A., Koran, L. M., Shear, M. K., Goodman, W. K., & Genduso, L. A. (2022). A Multicenter Investigation of Fixed-Dose Fluoxetine in the Treatment of Obsessive-compulsive Disorder. Routledge eBooks. https://doi.org/10.4324/9780203822937-24
743. Tong, G., Groom, K. N., Ward, L., & Naeem, M. Y. (2021). “This Is Not the Original Timeline”: A Case Report of an Extended Dissociative Episode in a Healthy Young Male Accompanied with Severe Decline in Mental State. Case Reports in Psychiatry. https://doi.org/10.1155/2021/6619579
744. Toom, K., Braschinsky, M., Obermann, M., & Katsarava, Z. (2020). Secondary headache attributed to exposure to or overuse of a substance. Cephalalgia. https://doi.org/10.1177/0333102420942238
745. Toro, V. D., Aedo, K., & Urrejola, P. (2021). Trastorno de Evitación y Restricción de la Ingesta de Alimentos (ARFID): Lo que el pediatra debe saber. Andes pediatrica. https://doi.org/10.32641/andespediatr.v92i2.2794
746. Torre, R. D. L., Farré, M., Roset, P. N., Pizarro, N., Abanades, S., Segura, M., Segura, J., & Camı́, J. (2004). Human Pharmacology of MDMA. Therapeutic Drug Monitoring. https://doi.org/10.1097/00007691-200404000-00009
747. Torrens, M., Martínez-Sanvisens, D., Martinez-Riera, R., Bulbena, A., Szerman, N., & Ruiz, P. (2011). Dual Diagnosis. Addictive Disorders & Their Treatment. https://doi.org/10.1097/adt.0b013e318215f322
748. Touze, M.-D., Potel, G., & Baron, D. (1993). [Acute ethyl alcohol intoxication].. PubMed.
749. Travers, C., MacAndrew, M., Hines, S., O’Reilly, M., Fielding, E., Beattie, E., & Brooks, D. (2015). The effectiveness of meaningful occupation interventions for people living with dementia in residential aged care: a systematic review protocol. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/01938924-201513040-00008
750. Travers, C., MacAndrew, M., Hines, S., O’Reilly, M., Fielding, E., Beattie, E., & Brooks, D. (2015). The effectiveness of meaningful occupation interventions for people living with dementia in residential aged care: a systematic review protocol. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/jbisrir-2015-2058
751. Trigo, M., Ganhão, I., Paixão, A., Pedro, P., & Gonçalves, E. (2010). P03-212 - Messing With Pleasure: A Smoking Cessation Program In A Psychiatric Hospital. European Psychiatry. https://doi.org/10.1016/s0924-9338(10)71266-9
752. Trill, M. D. (2012). Psychological aspects of depression in cancer patients: an update. Annals of Oncology. https://doi.org/10.1093/annonc/mds350
753. Trivedi, M. S., Hershman, D. L., & Crew, K. D. (2015). Management of Chemotherapy-Induced Peripheral Neuropathy. American Journal of Hematology / Oncology®.
754. Tsai, L., & Liou, H. (2015). Current Treatment for Generalized Convulsive Status Epilepticus in Adults.. PubMed.
755. Turki, T. A. A., & Arabia, S. (2002). The Emergence of Agitation and Suicide Ideation Secondary to the use of Fluoxetine Therapy: A Case Report.
756. Tyler, R. E., & Leggio, L. (2024). Biological basis of addiction and alcohol use disorder. Clinical Liver Disease. https://doi.org/10.1097/cld.0000000000000177
757. Uddin, M. S., Sufian, M. A., Kabir, M. T., Hossain, M. F., Nasrullah, M., Islam, I., Mamun, A. A., Islam, M. T., & Khanum, S. (2017). Amphetamines: Potent Recreational Drug of Abuse. Journal of Addiction Research & Therapy. https://doi.org/10.4172/2155-6105.1000330
758. Ungar, A. K., Konova, A. B., Patel, A. N., Goldstein, R. Z., & Hurd, Y. L. (2016). Substance Use and Addictive Disorders. https://doi.org/10.1002/9781118654231.ch16
759. Uppalapati, M., Strohl, K. P., & Sibilia, R. (2021). 854 Sexsomnia in a Divorce Proceeding and its Custody Implications. SLEEP. https://doi.org/10.1093/sleep/zsab072.851
760. Urban‐Kowalczyk, M., Rudecki, T., Wróblewski, D., & Rabe‐Jabłońska, J. (2012). [Psychotic disorders related with chronic use of mephedrone. Case report].. PubMed.
761. Valente, S. M. (2015). Evaluating and Managing Insomnia: Non-pharmacological Treatments. Journal of Sleep Disorders & Therapy. https://doi.org/10.4172/2167-0277.1000189
762. Vanderschuren, L. J. M. J. (2008). Neurobehavioral Mechanisms of Compulsive Drug Seeking. https://doi.org/10.1093/oso/9780195300550.003.0009
763. Varı̀, M. R., Pichini, S., Giorgetti, R., & Busardò, F. P. (2018). New psychoactive substances—Synthetic stimulants. Wiley Interdisciplinary Reviews Forensic Science. https://doi.org/10.1002/wfs2.1197
764. Velásquez-Martínez, M. C., & Ortíz, J. G. (2014). Abuso de Drogas: Generalidades Neurobiológicas y Terapéuticas. Actualidades en Psicología. https://doi.org/10.15517/ap.v28i117.14135
765. Verhagen, E. H., Hesselmann, G. M., Besse, T. C., & Graeff, A. D. (2005). [Palliative sedation].. PubMed.
766. Verma, S., & Agrawal, R. (2021). The lasting effects of childhood trauma. Current psychiatry. https://doi.org/10.12788/cp.0101
767. Vijay, P., Aziz, S., & Chaudhury, S. (2023). A Rare Case of Very Young-Onset Dementia Presenting as Conversion Disorder. Medical Journal of Dr D Y Patil Vidyapeeth. https://doi.org/10.4103/mjdrdypu.mjdrdypu_174_23
768. Vilibić, M., Jukić, V., Vidović, A., & Brečić, P. (2013). Cobalamin deficiency manifested with seizures, mood oscillations, psychotic features and reversible dementia in the absence of typical neurologic and hematologic signs and symptoms: a case report.. PubMed.
769. Vivanco, E. F., Gómez, C. P., & Martínez, R. G. (2006). Patología orgànica por drogas de síntesis. Adicciones.
770. Vlierden, K. V., & Lammar, P. (2006). Drugs and medicines in traffic : literature study..
771. Vliet, I. M. V. (1999). [A hidden compulsion].. PubMed.
772. Volkow, N. D., & Swanson, J. M. (2008). Does Childhood Treatment of ADHD With Stimulant Medication Affect Substance Abuse in Adulthood?. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2008.08020237
773. Voon, V., Thomsen, T., Miyasaki, J. M., Souza, M. D., Shafro, A., Fox, S. H., Duff‐Canning, S., Lang, A. E., & Zurowski, M. (2007). Factors Associated With Dopaminergic Drug–Related Pathological Gambling in Parkinson Disease. Archives of Neurology. https://doi.org/10.1001/archneur.64.2.212
774. Vázquez, G., Forte, A., Camino, S., Tondo, L., & Baldessarini, R. J. (2017). Treatment implications for bipolar disorder co-occurring with anxiety syndromes and substance abuse. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198748625.003.0017
775. Wadhwa, R., & Khandare, M. (2014). Stress Management through Yoga. Global Journal of Human-Social Science.
776. Walker, A. E. (2023). Custody and Restraint Deaths. CRC Press eBooks. https://doi.org/10.1201/9781003138754-30
777. Walterscheid, B., Eshak, N., & Nugent, K. (2021). Altered mental status in a patient with psychiatric history: Medication noncompliance or medical etiology?. Journal of Investigative Medicine.
778. Wand, G. S. (2008). The influence of stress on the transition from drug use to addiction.. PubMed.
779. Wang, S. (2001). Analysis on the 30 Cases of the Mental Barriers Caused by Taking Some Anti-psychosis Drugs. Journal of Inner Mongolia University for Nationalities.
780. Wang, S., Möller, H., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C. (2013). Asenapine, Blonanserin, Iloperidone, Lurasidone, and Sertindole. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0b013e3182aa38c4
781. Wankhade, S. P., & Gibbs, J. (2024). Alcohol Dependence Syndrome With Bipolar Affective Disorder and Hypomanic Current Episode: A Case Report. Cureus. https://doi.org/10.7759/cureus.55994
782. Ward, J., Hall, K., & Haslam, C. (2006). Patterns of Memory Dysfunction in Current and 2-year Abstinent MDMA Users. Journal of Clinical and Experimental Neuropsychology. https://doi.org/10.1080/13803390490918174
783. Ward, M., Macfarlane, J. T., Banks, D., Pilkington, R., & Finch, R. (1981). Reducing risks from intravenous cannulae.. BMJ. https://doi.org/10.1136/bmj.282.6279.1838
784. Wdowiak, K., Maciocha, A., Julia, Witas, A., Drogoń, J., Chachaj, W., Słomka, P., Gwóźdź, E., Konieczko, D., & Gardocka, E. (2024). issue of recreational use of sildenafil. Journal of Education Health and Sport. https://doi.org/10.12775/jehs.2024.66.55563
785. Weibel, S., Mallaret, M., Bennouna-Greene, M., & Bertschy, G. (2013). 2824 – Acute psychosis and buprenorphine withdrawal: abrupt vs. progressive could make a difference. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77409-1
786. Weiss, B., Clarkson, T. W., & Simon, W. (2002). Silent latency periods in methylmercury poisoning and in neurodegenerative disease.. Environmental Health Perspectives. https://doi.org/10.1289/ehp.02110s5851
787. Weller, E. B., Weller, R. A., & Dogin, J. W. (1998). A rose is a rose is a rose. Journal of Affective Disorders. https://doi.org/10.1016/s0165-0327(98)00180-3
788. Wesson, D. R., Smith, D. E., Ling, W., & Sabnani, S. (2008). Substance Abuse: Sedative, Hypnotic, or Anxiolytic Use Disorders. Psychiatry. https://doi.org/10.1002/9780470515167.ch64
789. White, C. M. (2014). How MDMA's Pharmacology and Pharmacokinetics Drive Desired Effects and Harms. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.266
790. Wick, J. Y., & Zanni, G. R. (2011). Helping Those with Hoarding Behaviors. The Consultant Pharmacist. https://doi.org/10.4140/tcp.n.2011.458
791. WIGUNA, G. R. P., & ARYANI, L. N. A. (2024). DEPRESI PADA REMAJA DENGAN ADIKSI TELAAH SISTEMATIS. KNOWLEDGE Jurnal Inovasi Hasil Penelitian dan Pengembangan. https://doi.org/10.51878/knowledge.v4i2.3265
792. Wilens, T. E. (1998). AOD use and attention deficit/hyperactivity disorder.. PubMed.
793. Williams, R. H., & Erickson, T. B. (2000). Evaluating Hallucinogenic or Psychedelic Drug Intoxication in an Emergency Setting. Laboratory Medicine. https://doi.org/10.1309/v3j8-3kw2-bpt1-fu15
794. Wilson, B. (1991). The Effect of Drugs on Male Sexual Function and Fertility. The Nurse Practitioner. https://doi.org/10.1097/00006205-199109000-00009
795. Winstock, A., & Schifano, F. (2012). Disorders relating to the use of ecstasy and other ‘party drugs’. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0066
796. Winston, A. P., Hardwick, E., & Jaberi, N. (2005). Neuropsychiatric effects of caffeine. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.11.6.432
797. Winters, K. C., & Ingwalson, A. (2022). Internalizing and Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0006
798. Winters, K. C., & Ingwalson, A. (2022). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0005
799. Wise, R. A. (1982). Neuroleptics and operant behavior: The anhedonia hypothesis. Behavioral and Brain Sciences. https://doi.org/10.1017/s0140525x00010372
800. Wojtyła-Buciora, P., Grzelak, T., Giermaziak, W., Mikołajczak, R., Kapka‐Skrzypczak, L., & Mądry, E. (2023). Novel Psychoactive Substances as a Vital and Ever-Changing Concern in Public Health. https://doi.org/10.2478/bgbl-2023-0016
801. Wolf, B. C., & Griffiths, R. R. (1991). Physical dependence on benzodiazepines: differences within the class. Drug and Alcohol Dependence. https://doi.org/10.1016/0376-8716(91)90044-y
802. Wood, G. W. (2006). Intramedullary nailing of femoral and tibial shaft fractures. Journal of Orthopaedic Science. https://doi.org/10.1007/s00776-006-1061-6
803. Wulandari, A., Kusuma, M. D., & Pancarani, R. (2023). Bipolar disorder - difficulties in managing emotional ups and down in an entertainer life: a case report. https://doi.org/10.35990/amhs.v1n3.p137-143
804. Wyatt, J. P., Illingworth, R. N., Graham, C. A., Hogg, K., Clancy, M., & Robertson, C. E. (2012). Environmental emergencies. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199589562.003.0006
805. Xiang, Q., Xu, L., Feng, Y., Ye, A., Liu, B., & Tan, Y. (2025). Increased Recall of Negative Memories Following Initial Methylphenidate Administration in a 6‐Year‐Old Boy With <scp>ADHD</scp>: A Case Report. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.70026
806. Yarlagadda, A. R., Brown, A. B., & Clayton, A. H. (2007). Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611h
807. Yennurajalingam, S., & Bruera, É. (2015). Fatigue and asthenia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199656097.003.0081
808. Yersin, B. (1999). [Ambulatory management of alcohol withdrawal syndrome].. PubMed.
809. Yonkers, K. A. (2004). Panic and Agoraphobia: Gender as a Factor. CNS Spectrums. https://doi.org/10.1017/s1092852900001991
810. Young, C., & Horton, J. (2019). Canine and Equine Therapy for Mental Health: A Review of Clinical Effectiveness [Internet].
811. Yu, R. C., & Conermann, T. (2024). Substance Use Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197584569.003.0071
812. Yudofsky, S. C., Silver, J., & Anderson, K. (2013). Aggressive Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625154.da10
813. Zagnoni, P., & Albano, C. (2002). Psychostimulants and Epilepsy. Epilepsia. https://doi.org/10.1046/j.1528-1157.2002.043s2028.x
814. Zainab, A., Shabbir, D., Waqar, K., & Mehmood, A. (2023). Consumption of Cannabis: A Risk Factor or a Therapeutic Agent for Patients with Schizophrenia. https://doi.org/10.1007/978-981-19-7022-1_15
815. Zaman, M., Aljeshi, A., Kuraga, K., Bunni, S., Sarker, T., Kashif, A. W., Sathish, J., Abouzeid, H., Alouf, H., Chinthamraks, J., Krishnan, A., Patker, S., Talreja, S., & Pentapati, D. (2025). Recreational Drugs Addiction, Withdrawal and its Impact on the body: A Literature Review. Medical Research Archives. https://doi.org/10.18103/mra.v13i3.6295
816. Zanini, R. S., Almeida, G. M. F. D., Helegda, L. C., & Fernandes, K. C. (2014). DEMENCIA DE WERNICKE KORSAKOFF, USO E ABUSO DE SUBSTANCIAS: REPERCUSSÕES NEUROPSICOLÓGICAS E PSICOMOTORAS.. Fiep Bulletin - online.
817. Zheng, J.-W., Meng, S., Liu, W.-Y., Chang, X., & Shi, J. (2023). [Appropriate Use and Abuse of Sedative-Hypnotic Drugs].. PubMed. https://doi.org/10.12182/20230260302
818. Zoorob, R., Kowalchuk, A., & Grubb, M. D. (2018). Buprenorphine Therapy for Opioid Use Disorder.. PubMed.
819. Zulkifli, N., Khuzaini, A. M., Aziz, A. A., & Awang, H. (2023). Trauma-related hallucination in an 8-year-old child with dissociative symptoms. Deleted Journal. https://doi.org/10.4103/mjp.mjp_10_23
820. Çorumlu, E. P., Aydın, O. Ö., Aydın, E. G. G., & Ulupınar, E. (2015). Effects of single-dose ketamine infusion on behavioral parameters and neuronal activation in the medial prefrontal cortex of juvenile rats exposed to prenatal stress. Anatomy (International Journal of Experimental and Clinical Anatomy). https://doi.org/10.2399/ana.15.027